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A B S T R A C T
Background
Cryptococcal disease remains one of the main causes of death in HIV-positive people who have low cluster of differentiation 4 (CD4)
cell counts. Currently, the World Health Organization (WHO) recommends screening HIV-positive people with low CD4 counts
for cryptococcal antigenaemia (CrAg), and treating those who are CrAg-positive. This Cochrane Review examined the effects of an
approach where those with low CD4 counts received regular prophylactic antifungals, such as fluconazole.
Objectives
To assess the efficacy and safety of antifungal drugs for the primary prevention of cryptococcal disease in adults and children who are
HIV-positive.
Search methods
We searched the CENTRAL, MEDLINE PubMed, Embase OVID, CINAHL EBSCOHost, WHO International Clinical Trials
Registry Platform (WHO ICTRP), ClinicalTrials.gov, conference proceedings for the International AIDS Society (IAS) and Conference
on Retroviruses and Opportunistic Infections (CROI), and reference lists of relevant articles up to 31 August 2017.
Selection criteria
Randomized controlled trials of adults and children, who are HIV-positive with low CD4 counts, without a current or prior diagnosis
of cryptococcal disease that compared any antifungal drug taken as primary prophylaxis to placebo or standard care.
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Data collection and analysis
Two review authors independently assessed eligibility and risk of bias, and extracted and analysed data. The primary outcome was all-
cause mortality.We summarized all outcomes using risk ratios (RR) with 95% confidence intervals (CI). Where appropriate, we pooled
data in meta-analyses. We assessed the certainty of the evidence using the GRADE approach.
Main results
Nine trials, enrolling 5426 participants, met the inclusion criteria of this review. Six trials administered fluconazole, while three trials
administered itraconazole.
Antifungal prophylaxis maymake little or no difference to all-cause mortality (RR 1.07, 95%CI 0.80 to 1.43; 6 trials, 3220 participants;
low-certainty evidence). For cryptococcal specific outcomes, prophylaxis probably reduces the risk of developing cryptococcal disease
(RR 0.29, 95% CI 0.17 to 0.49; 7 trials, 5000 participants; moderate-certainty evidence), and probably reduces deaths due to
cryptococcal disease (RR 0.29, 95% CI 0.11 to 0.72; 5 trials, 3813 participants; moderate-certainty evidence). Fluconazole prophylaxis
may make no clear difference to the risk of developing clinically resistant Candida disease (RR 0.93, 95% CI 0.56 to 1.56; 3 trials,
1198 participants; low-certainty evidence); however, there may be an increased detection of fluconazole-resistant Candida isolates from
surveillance cultures (RR 1.25, 95% CI 1.00 to 1.55; 3 trials, 539 participants; low-certainty evidence). Antifungal prophylaxis was
generally well-toleratedwith probably no clear difference in the risk of discontinuation of antifungal prophylaxis compared with placebo
(RR 1.01, 95% CI 0.91 to 1.13; 4 trials, 2317 participants; moderate-certainty evidence). Antifungal prophylaxis may also make no
difference to the risk of having any adverse event (RR 1.07, 95% CI 0.88 to 1.30; 4 trials, 2317 participants; low-certainty evidence),
or a serious adverse event (RR 1.08, 95% CI 0.83 to 1.41; 4 trials, 888 participants; low-certainty evidence) when compared to placebo
or standard care.
Authors’ conclusions
Antifungal prophylaxis reduced the risk of developing and dying from cryptococcal disease. Therefore, where CrAG screening is not
available, antifungal prophylaxismay be used in patients with lowCD4 counts at diagnosis andwho are at risk of developing cryptococcal
disease.
P L A I N L A N G U A G E S U M M A R Y
Preventing cryptococcal disease in HIV-positive people
What is the aim of this review?
The aim of this Cochrane Review was to find out if taking an antifungal drug regularly, such as fluconazole, prevented HIV-positive
people who have low cluster of differentiation 4 (CD4) cell counts, from getting cryptococcal disease, and what the potential compli-
cations were. Cochrane researchers collected and analysed all relevant studies to answer this question, and found nine trials that looked
at this question.
Key messages
We found that regularly taking antifungal medication prevented HIV-positive people who had low CD4 counts from developing
cryptococcal disease.We also found that primary prophylaxis probably reduced the number of people dying specifically fromcryptococcal
disease. However it probably did not reduce the number of people dying overall.
What was studied in the review?
Cryptococcal disease is one of the leading causes of death forHIV-positive people who have lowCD4 counts. The current recommended
strategy in most countries to prevent people from developing cryptococcal disease, is to screen eligible patients with a blood test that
picks up early signs of disease. We looked at trials that studied whether taking antifungal prophylaxis stopped people from dying or
developing cryptococcal disease. We also looked at the side effects of the antifungal drug and whether it caused resistance to antifungal
drugs in other fungal infections, such as thrush.
What are the main results of the review?
We found nine trials that included 5426 participants. These trials were conducted in Australia, Canada, South Africa, the UK, the
USA,Thailand, and sub-Saharan Africa. Seven trials were conducted before the availability of modern antiretroviral therapy. The
participants in two large trials received modern HIV treatment regimens.
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We found that antifungal prophylaxis may have no effect on death overall, although it reduced the risk of those with low CD4 counts
developing cryptococcal disease by 71%. Prophylaxis with an antifungal probably also reduced deaths specifically from cryptococcal
disease. There may be an increased risk of the vaginal tract becoming colonized with fluconazole-resistant Candida organisms if someone
takes prophylaxis, however, this may not necessarily result in an increased risk of clinical disease that doesn’t respond to treatment.
Generally, there were few side effects of taking antifungal prophylaxis, and it was well-tolerated when compared to placebo.
How up to date is this review?
The review authors searched for studies that had been published up to 31 August 2017.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antifungal prophylaxis versus no antifungal prophylaxis
Patient or population: people who are HIV-posit ive
Setting: global
Intervention: ant if ungal prophylaxis
Comparison: no ant if ungal prophylaxis
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
Number of participants
(trials)
Certainty of the evidence
(GRADE)
Risk with no antifungal pro-
phylaxis
Risk with antifungal pro-
phylaxis
All-cause mortality 111 per 1000 119 per 1000
(89 to 159)
RR 1.07
(0.80 to 1.43)
3220
(6 RCTs)
⊕⊕©©
Lowa,b,c
Cryptococcal disease oc-
currence
30 per 1000 9 per 1000
(5 to 15)
RR 0.29
(0.17 to 0.49)
5000
(7 RCTs)
⊕⊕⊕©
Moderated,e
Mortality due to cryptococ-
cal disease
11 per 1000 3 per 1000
(1 to 9)
RR 0.29
(0.11 to 0.72)
3813
(5 RCTs)
⊕⊕⊕©
Moderatee,f
Clinical resistance of Can-
dida species to f luconazole
49 per 1000 46 per 1000
(28 to 77)
RR 0.93
(0.56 to 1.56)
1198
(3 RCTs)
⊕⊕©©
Lowg,h
Microbiological resistance
of Candida to f luconazole:
surveillance sampling
348 per 1000 435 per 1000
(348 to 539)
RR 1.25
(1.00 to 1.55)
539
(3 RCTs)
⊕⊕©©
Low i,j
Treatment discont inuat ion 259 per 1000 262 per 1000
(236 to 293)
RR 1.01
(0.91 to 1.13)
2317
(4 RCTs)
⊕⊕⊕©
Moderateb
Any serious adverse event 153 per 1000 165 per 1000
(127 to 215)
RR 1.08
(0.83 to 1.41)
888
(4 RCTs)
⊕⊕©©
Low b,c,k
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Any adverse events 320 per 1000 342 per 1000
(281 to 415)
RR 1.07
(0.88 to 1.30)
2317
(4 RCTs)
⊕⊕©©
Lowb,l
*The risk in the intervention group (and its 95%CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: conf idence interval; RR: risk rat io; OR: odds rat io; ART: ant iretroviral therapy
GRADE Working Group grades of evidence
High certainty: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: we are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: we have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aNot downgraded for inconsistency. I² stat ist ic = 39%
bDowngraded two for indirectness. Part icipants in most of the included studies did not receive current standard ART regimens,
nor did they receive them in a t ime period consistent with current pract ice.
cNot downgraded for imprecision as narrow CIs around absolute risk
dDowngraded by one for indirectness. In the largest study, which contributed 47.2% to the pooled est imate of ef fect,
part icipants received current standard of care in type and t ime f rom diagnosis to ART (Hakim 2017).
eNot downgraded for imprecision; although there were few events, CIs around absolute risk were narrow, containing only
clinically appreciable benef it
fDowngraded by one for indirectness. Most trials were unclear in how they attributed death to cryptococcal disease. In the
largest study, which contributed 68.8% to the pooled est imate of ef fect, part icipants received current standard of care in type
and t ime f rom diagnosis to ART (Hakim 2017).
gDowngraded one for inconsistency. Clinical heterogeneity in how clinical resistance was def ined
hDowngrade one for imprecision. Few events in intervent ion and control groups.
iDowngraded one for indirectness. Surveillance sampling did not direct ly relate to clinical disease.
jDowngraded one for imprecision. Broad CIs around absolute risk contained clinically appreciable harm and no appreciable
ef fect.
kDowngraded one for indirectness. Studies did not clearly def ine grading of serious adverse events.
lDowngraded one for inconsistency. Unexplained heterogeneity of I² stat ist ic = 64%.
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B A C K G R O U N D
Description of the condition
Cryptococcal disease is an opportunistic infection that is common
among people who are HIV-positive with low cluster of differen-
tiation 4 (CD4) cell counts. In 2014, the global prevalence was
6% (Rajasingham 2017). It is a leading cause of morbidity and
mortality, both before and after initiation of anti-retroviral ther-
apy (ART) in patients with low CD4 counts (Jarvis 2010). It is
mostly caused by infection with Cryptococcus neoformans. Crypto-
coccus gattii is responsible in some cases. Patients may present with
meningitis, pneumonia, or in some rare cases, cutaneous, oph-
thalmic, or prostatic lesions (Skolnik 2017). Cryptococcal menin-
gitis is the commonest presentation of HIV-related cryptococcal
disease in adults. It is the leading cause of meningitis in adults in
sub-Saharan Africa, and accounts for 15% of HIV-related deaths
globally (Rajasingham 2017). The case fatality rate in sub-Saharan
Africa ranges from 35% to 65%, compared with 10% to 20% in
most high-income countries (Lessells 2011). While high-income
countries have seen considerable reduction in the incidence of
cryptococcal meningitis following increased access to ART (Mirza
2003), low-income countries have not experienced the same de-
cline (Tenforde 2017; Wall 2014; Williamson 2017). This may
be attributed to late diagnosis of HIV and delays in starting ART
in these settings (Kambugu 2008). In some settings, over 50% of
HIV-positive people and presenting with cryptococcal meningitis
are ART-experienced (Rhein 2016).
There are various diagnostic tools available for the detection of
cryptococcal disease. Cryptococcal meningitis can be diagnosed
through cerebrospinal fluid (CSF) microscopy, culture, or crypto-
coccal antigen detection. A positive cryptococcal antigen (CrAg)
test does not confer diagnosis, as HIV-positive people with ad-
vanced disease can be CrAg-positive weeks to months before the
development of cryptococcal meningitis. India ink microscopy of
CSF is the commonest technique, but has reduced sensitivity if the
fungal burden is low. CSF culture, considered the gold standard,
has a higher yield than India ink, but may also have poorer sensi-
tivity with low fungal burdens. CSF cryptococcal antigen testing
is highly sensitive and specific for cryptococcal meningitis, and is
available as a point-of-care rapid test. Blood culture, or serum or
plasma cryptococcal antigen testing, can be used to detect dissemi-
nated infection (CDC 2017). Pulmonary cryptococcal disease can
be detected through cryptococcal antigen testing of bronchoalve-
olar fluid; however, the sensitivity of this test is low, and the defini-
tive diagnosis is made through histopathology, cytopathology, or
culture of respiratory specimens or biopsies.
Description of the intervention
Prophylaxis for the prevention of opportunistic infections, such
as Pneumocytis (PJP) is an integral component of HIV care, and
has been shown to reduceHIV-associated mortality among people
with low CD4 counts (WHO 2016). When primary prophylaxis
for cryptococcal disease is administered, typically, antifungals are
used. A previous version of this Cochrane Review showed that
primary prophylaxis with fluconazole or itraconazole reduced the
incidence of cryptococcal disease, but had no effect on mortality
(Chang 2005).
Oral fluconazole is well-absorbed and well-tolerated, without
significant adverse events (McLachlan 1996). It is commonly
used for secondary prophylaxis of cryptococcal meningitis af-
ter successful treatment, to prevent relapse (WHO 2011). Long
periods of monotherapy for primary or secondary prophylaxis
may increase the risk of cryptococcal resistance to fluconazole
(Apisarnthanarak 2008b; Cheong 2013), especially in patients
whose CD4 cell counts are falling (Kontoyiannis 2002). A sys-
tematic review showed that primary fluconazole prophylaxis may
result in increased risk of colonization with susceptible dose-de-
pendent or resistant yeasts; however, no effect was seen on the risk
of resistant systemic fungal infection (Brion 2007). The concern
remains that with widespread use of antifungal prophylaxis, re-
sistant fungal strains will render antifungals ineffective, resulting
in refractory or relapsed cases of cryptococcal meningitis in HIV-
positive people.
Oral itraconazole does not absorb as well as fluconazole, and its
bioavailability is markedly influenced by gastric contents. Erratic
absorption with the capsule formulation, and high rates of gas-
trointestinal intolerance with the oral solution, have led to de-
creased use of this antifungal agent in recent years (Pound 2011).
In addition, drug interactions mediated through the cytochrome
P450 enzyme system may further limit the use of itraconazole as
part of a multi-drug regimen (Pierard 2000).
How the intervention might work
There are two broad approaches to preventing cryptococcal dis-
ease. The firstmethod (primary prophylaxis) consists of treating all
those with a low CD4 count with prophylactic antifungals, while
simultaneously initiating ART. This prevents cryptococcal disease
during the period of immune recovery. The second method of
controlling cryptococcal disease involves screening and pre-emp-
tive treatment. This method has been recommended by theWorld
Health Organization (WHO), and relies on the ability to detect
cryptococcal antigen in the blood. Patients who are HIV-positive,
and have severe disease with low CD4 counts, are tested for the
presence of cryptococcal antigen in blood; if positive, they are in-
vestigated for cryptococcal disease, and treated with antifungals
(WHO 2011).
Both methods have advantages and disadvantages. Primary pro-
phylaxis has been shown to be effective at reducing the incidence of
cryptococcal meningitis at a population level, but is less cost effec-
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tive (Micol 2010). Prior to this review, the use of prophylactic an-
tifungals in cryptococcal antigen negative patients with low CD4
counts was only recommended by the WHO if a prolonged delay
in ART initiation was likely. This recommendation was based on
the lack of a consistent survival benefit associated with primary
prophylaxis, costs associated with providing prophylaxis to a large
number of people, and concerns over drug resistance and congen-
ital anomalies (WHO 2011).
The focus of this review was solely on the effects of primary pro-
phylaxis with an antifungal agent. However, these are not, and
should not, be considered mutually exclusive interventions.
The optimal CD4 count level at which primary antifungal pro-
phylaxis should be initiated is unclear. Different studies have
reported initiating treatment at < 50 cells/µL (Micol 2010), <
100 cells/µL (Chetchotisakd 2004; Micol 2010), < 200 cells/µL
(Parkes-Ratanshi 2011), and < 300 cells/µL (Smith 2001), with
varying cost-effectiveness.
Why it is important to do this review
The previous published version of this review showed that primary
antifungal prophylaxis with either itraconazole or fluconazole was
effective in reducing the incidence of cryptococcal disease in adults
with advanced HIV disease. However, the effect on overall mor-
tality was unclear (Chang 2005). Since the review’s publication, a
number of new, relevant trials have been published. Another re-
view, which included observational studies in addition to random-
ized controlled trials (RCT), similarly concluded that primary an-
tifungal prophylaxis could prevent cryptococcal meningitis, but
not reduce all-cause mortality (Ssekitoleko 2013). However, the
scope of the review was limited to the adult population, and pub-
lications in English, in peer-reviewed journals, with an outdated
literature search.
In order to provide updated high-quality evidence, we restricted
our studies to RCTs, included paediatric populations, and non-
English publications, and conducted searches of the grey litera-
ture. The outputs of this review can contribute to the formulation
of future guideline recommendations for the prevention of cryp-
tococcal disease in adults and children who are HIV-positive.
O B J E C T I V E S
To assess the efficacy and safety of antifungals for the primary
prevention of cryptococcal disease in adults and children who are
HIV-positive.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included RCTs.
Types of participants
Adults and children who are HIV-positive, with low CD4 cell
counts, without a current or prior diagnosis of cryptococcal dis-
ease.
Types of interventions
Interventions
Triazole antifungals, used as primary prophylaxis to prevent fungal
infections.We considered drugswithin this class approved for clin-
ical use, such as itraconazole, fluconazole, voriconazole, posacona-
zole, and isavuconazole.
Control
Placebo or no antifungal intervention.
Types of outcome measures
Primary outcomes
• All-cause mortality: number of deaths from any cause/
number randomized
Secondary outcomes
• Cryptococcal disease:
◦ number of HIV-positive people diagnosed/number
randomized
◦ including episodes of: antigenaemia, meningitis, or
pneumonia during the follow-up period
⋄ diagnosis of antigenaemia: serum cryptococcal
antigen test, blood culture
⋄ diagnosis of meningitis: CSF India ink staining,
CSF culture, CSF cryptococcal antigen test
⋄ diagnosis of pneumonia: culture, histopathology,
or cytopathology of respiratory specimens
• Deaths due to cryptococcal disease: number of deaths
attributed to a diagnosis of cryptococcal meningitis
• Adherence: number categorized as adherent by authors/
number randomized
• Cryptococcal antifungal drug resistance: number
categorized as resistant by authors/number randomized
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• Infections caused by Candida species resistant to the
prophylactic antifungal drug: number with infections by
resistant Candida/number randomized
• Treatment discontinuation: number discontinuing regimen
due to adverse events, patient choice, pregnancy, or for any other
reason. This was only assessed in trials with placebo control arms.
• Adverse events:
◦ number with any reported adverse event/number
randomized
◦ in addition, severe (grades 3 to 5) hepatotoxicity
(elevated ALT and AST), anaemia, rash, diarrhoea, nausea, and
vomiting (categorized according to the Division of AIDS Table
for Grading severity of Adult and Paediatric adverse events) will
be evaluated as the number with severe adverse events/number
randomized for each of these events (DAIDS 2014).
Search methods for identification of studies
We attempted to identify all relevant studies, regardless of language
or publication status. We included all studies that addressed one
or more of our outcomes.
Electronic searches
We searched the following databases on 31 August 2017: the
Cochrane Central Register of Controlled Trials (CENTRAL;
2017, issue 8), published in the Cochrane Library; MEDLINE
PubMed; Embase OVID, and CINAHL EBSCOHost, using the
search strategies in Appendix 1.
We also searched the WHO International Clinical Trials Reg-
istry Platform (WHO ICTRP; www.who.int/ictrp/en/) and Clin-
icalTrials.gov (https://clinicaltrials.gov/ct2/home) on 31 August
2017, to identify ongoing trials.
Searching other resources
Grey literature
We actively searched for grey literature, by contacting researchers
in the field and searching for publications regardless of language.
We searched abstracts from the Conference on Retroviruses and
Opportunistic Infections (CROI) and the International AIDS
(IAS) conferences. We searched conference outputs from 2015,
2016, and 2017.
Reference lists
We checked the reference lists of all studies identified by the above
methods for other potentially relevant studies. We also searched
the reference lists and included studies of other systematic reviews.
Correspondence
We contacted researchers working in the field for unpublished and
ongoing trials.
Data collection and analysis
Selection of studies
Two review authors (AA and SJ) independently screened the titles
and abstracts of the search results to identify studies relevant to
this review. We resolved disagreements through consultation with
the third review author (IEW). We retrieved full-text articles of
potentially eligible trials. We included studies that met the prede-
fined inclusion criteria. We resolved disagreements by discussion
with the third review author.
Data extraction and management
Two review authors (AA and SJ) independently extracted data
from the included trials, using a standardized data extraction form,
whichwe created and piloted. For each trial, we extracted the study
design, risk of bias, participant characteristics (age, gender, ethnic-
ity, baseline CD4+ T cell count and viral load, use of ART, time
to ART, cryptococcal antigen status, endemicity of cryptococcus),
trial setting, interventions (antifungal type, dose, and duration),
duration of follow-up, treatment discontinuations, adverse events,
and reported outcomes.
We resolved disagreements in data extraction through consulta-
tion with the third review author (IEW). One author entered all
the extracted data into Review Manager 5 (RevMan 2014). An-
other review author independently checked the entered data for
accuracy. We contacted authors of primary trials for missing data.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias for each
included study, using the Cochrane ‘Risk of bias’ assessment tool
(Higgins 2011). We resolved disagreements through consultation
with the third review author. We contacted trial authors for clar-
ification when the risk of bias was unclear. We summarized the
results of the risk of bias for each included trial in the ‘Risk of bias’
tables.
Measures of treatment effect
We measured the treatment effect for dichotomous outcomes us-
ing risk ratios (RR). We calculated 95% confidence intervals (CI)
for all outcomes. We performed meta-analysis where there were
sufficient combinable data.
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Unit of analysis issues
We analysed the data at the level of the individual.
Dealing with missing data
We performed all analyses on an intention-to-treat basis, using the
total number of participants randomized as the denominator.
Assessment of heterogeneity
We assessed heterogeneity by visual inspection of the forest plots
for CIs overlap, and by using the Chi² test for heterogeneity. We
quantified the heterogeneity using the I² statistic. We used the
approach set out in the Cochrane Handbook for Systematic Reviews
of Interventions for statistical tests of heterogeneity.We interpreted
I² in the context of (i) magnitude and direction of effects and (ii)
strength of evidence for heterogeneity (e.g. P value from the Chi²
test, or a CI for I²). We classified heterogeneity as defined in the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011):
• 0% to 40%: might not be important
• 30% to 60%: may represent moderate heterogeneity
• 50% to 90%: may represent substantial heterogeneity
• 75% to 100%: considerable heterogeneity
We interrogated possible sources of heterogeneity, using subgroup
analysis.Wherewewere unable to explain significant heterogeneity
through subgroup analysis, we considered this when we assessed
certainty of evidence with the GRADE criteria.
Assessment of reporting biases
No analysis included more than 10 trials, so we were unable to
assess for publication bias.
Data synthesis
We analysed the data using Review Manager 5 (RevMan 2014).
We used the random-effects model for all meta-analyses, as we
considered the different studies to be estimating different, yet re-
lated, intervention effects (Higgins 2011).Where considerable un-
explained heterogeneity was detected, we did not pool the results.
Subgroup analysis and investigation of heterogeneity
We investigated potential sources of heterogeneity by performing
subgroup analyses for all-cause mortality and cryptococcal disease
outcomes on the following.
• CD4+ threshold for initiation of prophylaxis
• CrAg status at baseline
• Timing of ART initiation
• Type of ART
• Type of antifungal medication
Sensitivity analysis
We included all randomized trials in the meta-analysis, regardless
of their risk of bias.
We had intended to conduct sensitivity analyses for the primary
outcome by excluding trials with a high or unclear risk of bias for
the following.
• Attrition (> 20%)
• Sequence generation
• Allocation concealment
Assessing the certainty of the evidence
We evaluated the certainty of the evidence using the GRADE ap-
proach.We generated ‘Summary of findings’ tables usingGRADE-
pro GDT (GRADEpro GDT).
R E S U L T S
Description of studies
See Characteristics of included studies; Characteristics of excluded
studies; Characteristics of studies awaiting classification.
See Figure 1: Study flow diagram
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Figure 1. Study flow diagram.
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Results of the search
We retrieved 1069 records from our searches conducted between
1 January 1980 and 31 August 2017, using the terms in our
search strategy in Appendix 1. We identified 3 additional records
through other sources. After removing duplicates, we identified
1045 records, which we screened for relevance against our inclu-
sion criteria. We identified 41 records for full-text screening; of
these, we included nine randomized controlled trials (RCT) in 17
reports. The selection process is depicted in Figure 1.
Included studies
We included nine RCTs (17 records). See the ‘Characteristics of
included studies’ tables.
We also summarized key characteristics of these studies in Table
1, to aid interpretation of the data.
Design
We included nine RCTs, with a total of 5426 participants.
Two trials were conducted in Thailand (Chariyalertsak 2002;
Chetchotisakd 2004), four in theUSA (Goldman2005;McKinsey
1999; Revankar 1998; Schuman 1997), one in Uganda (Parkes-
Ratanshi 2011), and two were multi-centre trials conducted in
Uganda, Zimbabwe, Malawi, and Kenya (Hakim 2017), and Aus-
tralia, Canada, South Africa, and the UK (Smith 2001).
Participants
Most trials included both adults and adolescents, older than
13 years. One trial included adolescents over 15 years (Parkes-
Ratanshi 2011). One trial also included children older than five
years (Hakim 2017).
Six trials did not report on the cryptococcal antigen (CrAg) status
of their participants at baseline (Chariyalertsak 2002; Goldman
2005; McKinsey 1999; Revankar 1998; Schuman 1997; Smith
2001). Chetchotisakd 2004 and Parkes-Ratanshi 2011 reported
on the CrAg status of their participants at baseline, but excluded
the CrAg-positive patients. Hakim 2017 reported on the CrAg
status of participants at baseline, but did not exclude the CrAg-
positive patients.
Full inclusion and exclusion criteria are presented in the ‘
Characteristics of included studies’ table.
Interventions
Six trials randomly assigned HIV-positive participants to the anti-
fungal study drug or placebo (Chariyalertsak 2002; Chetchotisakd
2004; McKinsey 1999; Parkes-Ratanshi 2011; Schuman 1997;
Smith 2001). Two studies randomized participants to continu-
ous administration of antifungal prophylaxis or antifungals, as
needed for the treatment of candidiasis (Goldman 2005; Revankar
1998). Hakim 2017 assigned participants randomly to either
standard prophylaxis for Pneumocystis jiroveci pneumonia (PJP)
with trimethoprim-sulfamethoxazole or an enhanced prophylaxis
package consisting of 12 weeks of fluconazole (100 mg once a
day), one dose of albendazole 400 mg, five days of azithromycin
(500 mg once a day), 12 weeks of trimethoprim-sulfamethoxazole
(trimethoprim 160 mg once a day and sulfamethoxazole 800 mg
once a day), isoniazid 300 mg once a day, and pyridoxine 25 mg
once a day for 12 weeks.
The choices and doses of antifungal used included itracona-
zole 200 mg daily (Chariyalertsak 2002; McKinsey 1999; Smith
2001), fluconazole 100 mg daily (Hakim 2017), fluconazole 200
mg daily (Revankar 1998), fluconazole 200 mg three times per
week (Goldman 2005; Parkes-Ratanshi 2011), fluconazole 200
mg weekly (Schuman 1997), and fluconazole 400 mg weekly
(Chetchotisakd 2004).
Five included studies did not report if participants received co-
trimoxazole prophylaxis (Chetchotisakd 2004; Goldman 2005;
McKinsey 1999; Revankar 1998; Schuman 1997). Seventy-five
percent of participants in the treatment arm and 65% of partic-
ipants in the placebo arm received co-trimoxazole prophylaxis in
Smith 2001. One study reported that participants were offered
co-trimoxazole according to national guidelines (Parkes-Ratanshi
2011). All participants in two trials received standard co-trimox-
azole prophylaxis (Chariyalertsak 2002; Hakim 2017).
Participants in the Hakim 2017 and Parkes-Ratanshi 2011 trials
were all anti-retroviral therapy (ART)-naïve at the start of follow-
up, and then received current standard ART triple therapy, initi-
ated during the trial. Participant therapies in theHakim 2017 trial
initiated ART at a median of five days, as would be expected under
the current standard of care. Participants in the Parkes-Ratanshi
2011 study initiated ART at a median of 11 weeks. Five trials
included participants that were on a mix of a non-current stan-
dard ART regimen and no ART at baseline (Chariyalertsak 2002;
Goldman 2005; McKinsey 1999; Schuman 1997; Smith 2001).
HIV-positive participants in Chetchotisakd 2004 were all ART-
naïve at baseline, but they did not report which ART regimen they
initiated. One trial did not report the ART status of its participants
(Revankar 1998).
Outcome measures
Seven studies reported death as an outcome (Chariyalertsak 2002;
Chetchotisakd 2004; Goldman 2005; Hakim 2017; McKinsey
1999; Parkes-Ratanshi 2011; Smith 2001); we included six of these
studies in our analysis. Hakim 2017 reported all-cause mortality;
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however, the co-interventions used in this study, as described in
Table 1, could possibly have confounded any effect measured.
Therefore, we did not include this study in our meta-analysis for
this outcome. The CD4 cell count thresholds for initiation of
antifungal prophylaxis varied from < 100 cells/µL to < 300 cells/
µL. Duration of follow-up varied from 22 weeks to 42 months.
Seven studies reported the incidence of cryptococcal disease
(Chariyalertsak 2002; Chetchotisakd 2004; Goldman 2005;
Hakim 2017; McKinsey 1999; Parkes-Ratanshi 2011; Smith
2001). Six studies measured cryptococcal disease occurrence, and
used standard prophylaxis, consisting solely of an antifungal or
placebo as an adjunct to standard care.
Five studies reported mortality due to cryptococcal disease
(Chariyalertsak 2002; Chetchotisakd 2004; Hakim 2017;
McKinsey 1999; Parkes-Ratanshi 2011). In these studies, there
was variable reporting of the method of diagnosis of death due to
cryptococcal disease. Hakim 2017 measured cryptococcal disease
occurrence and used enhanced prophylaxis, which included co-
interventions, as described in Table 1. We did not deem these co-
interventions to be active onmortality due to cryptococcal disease,
and so included this study in the pooled estimate.
Only Chariyalertsak 2002 reported adherence to antifungal pro-
phylaxis.
Four studies reported clinically defined Candida resistance in pa-
tients enrolled in trials (Chariyalertsak 2002; Goldman 2005;
Revankar 1998; Schuman 1997). Chariyalertsak 2002 compared
Itraconazole to placebo, while Goldman 2005, Revankar 1998,
and Schuman 1997 compared fluconazole to placebo. We iden-
tified four studies that reported microbiologically-defined resis-
tance in Candida species isolated from patients enrolled in tri-
als (Goldman 2005; McKinsey 1999; Revankar 1998; Schuman
1997).
Four studies reported discontinuation of antifungal prophy-
laxis compared to placebo for any reason, and adverse events
(Chariyalertsak 2002; McKinsey 1999; Parkes-Ratanshi 2011;
Smith 2001).
Excluded studies
We excluded 22 studies after assessing the full-text articles (see
‘Characteristics of excluded studies’ table).
Studies awaiting classification
We were unable to retrieve the full-text reports of two studies to
assess them for inclusion (Smith 1999, Anonymous 1998).
Risk of bias in included studies
We have presented the ‘Risk of bias’ summary, which represents
the review authors’ judgements about each risk of bias item for
each included study in Figure 2.We have summarized our findings
for each domain below:
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Figure 2. ‘Risk of bias’ summary: review authors’ judgements about each ‘Risk of bias’ item for each
included study
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Allocation
Computer-generated randomization lists were used by
Chariyalertsak 2002;Hakim 2017; and Smith 2001. Random lists
were generated using permuted blocks in Parkes-Ratanshi 2011;
Revankar 1998; and Schuman 1997. Methods for sequence gen-
eration were not explicitly stated in Goldman 2005 andMcKinsey
1999. No methods for sequence generation were described for
Chetchotisakd 2004.
There was adequate concealment of treatment allocation in three
of the nine trials (Chariyalertsak 2002; Hakim 2017; Parkes-
Ratanshi 2011). The remaining six did not record any method of
allocation concealment.
Blinding
We judged all nine trials to be free of the risk of performance
bias, as all the participants received either the study medication or
matching placebo. Hakim 2017 was an open label trial, however,
we judged our main outcomes to be objective assessments, and
therefore not prone to performance bias.
We judged two of the nine trials as having unclear risk of detection
bias (Goldman 2005; Schuman 1997).
Incomplete outcome data
We judged Revankar 1998 as having high risk of attrition bias,
because a disproportionate number of participants in the inter-
vention and control groups were excluded from the trial, based on
death within three months of enrolment.
McKinsey 1999 and Chetchotisakd 2004 were assessed as having
unclear risk of attrition bias, because neither trial recorded any loss
to follow-up data.
The remaining six trials were judged as having low risk of attrition
bias.
Selective reporting
We assessed the risk of bias from selective outcome reporting to
be unclear in Chetchotisakd 2004, as the authors did not report
loss to follow-up, drop out rates, or adverse events in detail. The
other eight trials were assessed at low risk.
Other potential sources of bias
We assessed the risk of bias as high in the Revankar 1998 study,
because baseline characteristics and baseline ART status were not
described. Four trials were judged as having unclear risk, because
there was insufficient information available to make an assessment
on whether the funding received from pharmaceutical compa-
nies impacted the study design or analyses (Chariyalertsak 2002;
Chetchotisakd 2004; McKinsey 1999; Smith 2001). We judged
four trials at low risk of other potential sources of bias (Goldman
2005; Hakim 2017; Parkes-Ratanshi 2011; Schuman 1997).
Effects of interventions
See: Summary of findings for the main comparison Antifungal
prophylaxis versus no antifungal prophylaxis for preventing
cryptococcal disease in HIV-positive people
Primary outcomes
All-cause mortality
Antifungal prophylaxis had no consistent effect on all-cause mor-
tality (risk ratio (RR) 1.07, 95% CI 0.80 to 1.43; six trials, 3220
participants; Analysis 1.1). We could not include data for this out-
come from the most recent trial, which initiated ART a mean of
five days after screening, as there were co-interventions in the in-
tervention arm that would have confounded the effect on mortal-
ity (Hakim 2017).
Subgroup analyses
There was little difference in pooled effect estimates when we
subdivided all-cause mortality by: CD4 threshold for prophylaxis
(I² statistic = 0%; Analysis 1.2), baseline CrAG status (I² statistic
= 0%; Analysis 1.3), time-to-initiation of ART (I² statistic = 0%;
Analysis 1.4), ART regimens (I² statistic = 0%; Analysis 1.5), or
type of antifungal drug (I² statistic = 0%; Analysis 1.6).
Secondary outcomes
Cryptococcal disease occurrence
We excluded unconfirmed, suspected cases of cryptococcal disease
from our analysis. Hakim 2017 measured cryptococcal disease
occurrence, and used enhanced prophylaxis, which included co-
interventions described in Table 1. We did not deem these co-
interventions to be active on cryptococcal disease, so included this
study in the pooled estimate.
The seven studies that measured cryptococcal disease identified
91 cases. Most of the studies did not report the source of the cryp-
tococcal infection, simply referring to invasive cryptococcal dis-
ease. All 10 cases in Chetchotisakd 2004 were confirmed cases of
cryptococcal meningitis; Smith 2001 reported one case of cryp-
tococcal pneumonia and one case of cryptococcal meningitis.
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Parkes-Ratanshi 2011 confirmed 11 cases of cryptococcal menin-
gitis, five participants with invasive cryptococcal disease and posi-
tive blood cultures, and three participants who became CrAg-pos-
itive after starting prophylaxis. Hakim 2017 reported 32 new cases
of cryptococcal infection: 22 cases of cryptococcal meningitis, and
one case of cryptococcal fungaemia in the standard prophylaxis
arm, and nine cases of cryptococcal meningitis in the enhanced
prophylaxis arm.
Meta-analysis showed a large reduction in the risk of developing
cryptococcal disease in those who received antifungal prophylaxis.
Participants on antifungal prophylaxis were 71% less likely to de-
velop cryptococcal disease than those receiving placebo or stan-
dard care (RR 0.29, 95% CI 0.17 to 0.49; seven trials, 5000 par-
ticipants; Analysis 1.7). Benefit of antifungal prophylaxis was seen
consistently across the included studies, although this was not sta-
tistically significant at a 95% level of confidence in four of the
studies.
Subgroup analyses
There was no clear difference in effect estimates when we sub-
grouped cryptococcal disease occurrence by: CD4 threshold for
prophylaxis (I² 0%; Analysis 1.8), ART regimen (I² statistic = 0%;
Analysis 1.9), or type of antifungal drug (I² 0%; Analysis 1.10 ).
Subgrouping by time-to-initiation of ART showed a similar ben-
efit of prophylaxis across all subgroups, with a small amount of
heterogeneity (I² statistic = 36.9%; Analysis 1.11). There was no
clear difference between subgroups by baseline CrAG status (I²
statistic = 0%; Analysis 1.12). Proportionally fewer participants
who were CrAg-negative at baseline went on to develop crypto-
coccal disease (regardless of treatment arm) compared to CrAg-
positive cases. Few participants and one study contributed data to
the baseline CrAg-positive subgroup analysis (Hakim 2017).
Cryptococcal-specific mortality
People taking antifungal prophylaxis were less likely to die from
cryptococcal disease (RR 0.29, 95% CI 0.11 to 0.72; five trials,
3813 participants; Analysis 1.13).
No clear difference was seen in studies that excluded participants
who tested CrAG-positive, and those on current standard ART
regimens (one nucleoside reverse transcriptase inhibitor and two
non-nucleoside reverse transcriptase inhibitors).
Adherence
Chariyalertsak 2002 (129 participants) reported no significant dif-
ference in adherence between participants receiving antifungals
and placebo. Ninety-two per cent of those receiving antifungals
adhered to the regimen, while 85% of those receiving placebo ad-
hered.
Cryptococcal antifungal drug resistance
We did not identify any studies that reported cryptococcal anti-
fungal resistance.
Infections caused by Candida species resistant to the
prophylactic antifungal drug triazole
(a) Clinical resistance
Schuman 1997 compared fluconazole to placebo for the preven-
tion of candidiasis. Two open label trials compared the continu-
ous use of fluconazole prophylaxis for symptomatic treatment of
clinical Candida disease (Goldman 2005; Revankar 1998). Clin-
ical resistance was largely defined as participants who developed
Candida disease that did not respond to treatment with flucona-
zole; the exact definition varied between studies, as described in
Table 2. We subgrouped the results of this analysis by antifungal
therapy.
Subgroup analyses
Neither fluconazole prophylaxis (RR 0.93, 95% CI 0.56 to 1.56;
three trials, 1198 participants; Analysis 1.14) nor itraconazole pro-
phylaxis (RR 3.14, 95% CI 0.13 to 75.69; one trial, 129 partici-
pants; Analysis 1.14) showed a clear effect on the risk of develop-
ing Candida disease clinically resistant to the antifungal agent.
(b) Microbiological resistance
Three studies monitored resistance by taking surveillance cultures
obtained from mucosal swabs, and reporting all strains of Can-
dida resistant to fluconazole (Goldman 2005; Revankar 1998;
Schuman 1997). Goldman 2005 and Revankar 1998 reported re-
sistance in oropharyngeal swabs, and Schuman 1997 reported re-
sults from vaginal swabs. One study only reported Candida albi-
cans isolates (McKinsey 1999). McKinsey 1999 used itraconazole,
and reported both resistance to itraconazole and cross-resistance
to fluconazole, from swabs of any mucosa, from participants with
clinical disease.We defined resistance to fluconazole as aminimum
inhibitory concentration (MIC) > 16 µg/mL. All studies reported
this. Schuman 1997 reported participants with aMIC > 16 µg/mL
as ‘dose-dependent susceptible’. They reported absolute resistance
as MIC > 64 µg/mL. For this analysis, we combined participants
with these results to form an aggregate number of events withMIC
> 16 µg/mL (Table 3). There was marked qualitative heterogene-
ity between studies that reported on this outcome, as sampling
methods, antifungal drug, and Candida species detected differed
markedly between McKinsey 1999 and the remaining studies. As
a result, we chose not to pool estimates across all three studies.
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Subgroup analyses
Among the three studies using fluconazole prophylaxis and surveil-
lance sampling, antifungal prophylaxis was found to increase the
risk of developing microbiological resistance to fluconazole in all
Candida species (RR 1.25, 95% CI 1.00 to 1.55; three trials, 539
participants; Analysis 1.15). In the subgroup, which included one
study inwhich itraconazole prophylaxis was used and samples were
obtained from clinical disease, we found that antifungal prophy-
laxis increased the risk of developing microbiological cross-resis-
tance to fluconazole among C. albicans species (RR 6.19, 95% CI
1.41 to 27.10; one trial, 95 participants; Analysis 1.15; McKinsey
1999).
Treatment discontinuation
Four studies reported the discontinuation of antifungal prophy-
laxis compared to placebo for any reason (Chariyalertsak 2002;
McKinsey 1999; Parkes-Ratanshi 2011; Smith 2001). The reasons
included serious adverse events, hepatotoxicity, pregnancy, use of
contraindicated medications (such as rifampicin), and patient de-
cision (Table 4). We found no clear difference between those who
discontinued antifungal prophylaxis compared to placebo (RR
1.01, 95% CI 0.91 to 1.13; four trials, 2317 participants; Analysis
1.16).
Adverse events
We excluded Hakim 2017 from the analysis of adverse events, as
unpicking the effects of the co-interventions delivered in this trial
was not possible.
(a) Serious adverse events
Four studies reported serious adverse events (Chariyalertsak 2002;
Chetchotisakd 2004; McKinsey 1999; Smith 2001). These were
measured as the number of patients experiencing at least one seri-
ous adverse event. One study reported no adverse events in either
group (Chetchotisakd 2004). All studies were conducted before
2004, and as such, the participants were on a mix of older anti-
retroviral drugs, described inTable 1. There was no clear difference
in the occurrence of serious adverse events between participants
receiving antifungal prophylaxis and those receiving placebo. (RR
1.08, 95% CI 0.83 to 1.41; four trials, 888 participants; Analysis
1.17)
(b) Any adverse event
Four studies reported any adverse events (Chariyalertsak 2002;
McKinsey 1999; Parkes-Ratanshi 2011; Smith 2001).Three out
of the four studies were conducted before 2004, and as such, the
participants were on a mix of older anti-retroviral drugs, described
in Table 1. Adverse events were measured as the number of pa-
tients experiencing at least one adverse event. There was no clear
difference in the occurrence of adverse events between participants
receiving antifungal prophylaxis and those receiving placebo (RR
1.07, 95% CI 0.88 to 1.30; 4 trials; 2317 participants; Analysis
1.18).
No clear difference was found between groups for any of the most
commonly reported adverse events (Analysis 1.19).
• Diarrhoea (RR 1.31, 95% CI 0.32 to 5.29; 2 trials, 424
participants)
• Abdominal pain (RR 0.91, 95% CI 0.56 to 1.46; 2 trials,
1814 participants)
• Nausea (RR 0.97, 95% CI 0.64 to 1.47; 2 trials, 1814
participants)
• Rash (RR 1.03, 95% CI 0.56 to 1.9; 4 trials, 2317
participants)
D I S C U S S I O N
Summary of main results
See Summary of findings for the main comparison.
Nine trials, enrolling 5426 participants, met the inclusion criteria
of this Cochrane Review.
Antifungal primary prophylaxis alone may make little or no dif-
ference to all-cause mortality (low-certainty evidence). For cryp-
tococcal-specific outcomes, prophylaxis probably reduces the risk
of developing cryptococcal disease (moderate-certainty evidence),
and probably reduces deaths due to cryptococcal disease (moder-
ate-certainty evidence). It may make no clear difference to the risk
of developing clinically-resistant Candida disease (low-certainty
evidence); however, there may be an increased risk of having Can-
dida resistant to fluconazole isolated by surveillance cultures (low-
certainty evidence). Antifungal prophylaxis was generally well-tol-
erated, with no clear difference in the risk of needing to discon-
tinue antifungal prophylaxis compared with placebo (moderate-
certainty evidence), and no clear difference in the risk of having
any adverse event (low-certainty evidence) or a serious adverse
event (low-certainty evidence).
Potential benefits of antifungal prophylaxis
Antifungal prophylaxis probably reduces the risk of developing
cryptococcal disease. It also probably reduces the risk of dying
from cryptococcal disease.
Potential harms of antifungal prophylaxis
Antifungal prophylaxis is well tolerated, with no clear difference
in the occurrence of adverse events, and probably no clear differ-
ence in treatment discontinuations. Theremay be an increased risk
of developing fluconazole resistant Candida species, although this
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may not translate to disease resistant to treatment. In the absence
of cryptococcal antigen (CrAg) screening programmes and high
CrAg prevalence, primary prophylaxis could under-treat CrAg-
positive people who are HIV-positive with high titres and subclin-
ical meningitis. Itraconazole potentially interacts with common
first-line antiretrovirals (tenofovir, efavirenz) rendering it less suit-
able for widespread use compared to fluconazole, where there are
no interactions with current first line antiretrovirals (HIV drug
interactions 2018).
Overall completeness and applicability of
evidence
We included nine trials that evaluated the efficacy and safety of
interventions for preventing cryptococcal infection in HIV-posi-
tive people. Four of these trials were conducted in low- and mid-
dle-income countries, while the remaining five were conducted in
high-income countries. All participants were adults, even though
several studies included children and adolescents in eligibility cri-
teria.
Several studies included in this review were older and less rele-
vant to the contemporary HIV experience, due to changes in an-
tiretroviral therapy (ART) treatment regimens and timing of ART
initiation in recent years. Only two trials included participants
who received currently recommended triple ART (Hakim 2017;
Parkes-Ratanshi 2011), and in only one of these was ART initi-
ated within one to two weeks of HIV diagnosis, as would be the
current practice, particularly in patients with low CD4 cell counts
(Hakim 2017). In addition, three studies used itraconazole pro-
phylaxis, which is less commonly used, due to substantial drug
interactions (Chariyalertsak 2002; McKinsey 1999; Smith 2001).
Hakim 2017 evaluated a combination of interventions that in-
cluded antifungals, antibiotics, and anthelmintics, compared with
standard prophylaxis for pneumocystis using only co-trimoxazole.
Despite the finding that several studies did not represent the cur-
rent HIV care experience, the protective effect of prophylaxis was
consistent across all study populations, including those receiving
the current standard of HIV care.
Two studies excluded CrAg-positive patients prior to randomiza-
tion (Chetchotisakd 2004; Parkes-Ratanshi 2011). One study re-
ported baseline CrAg status after trial completion (Hakim 2017).
Among CrAg-negative participants, antifungal prophylaxis con-
tinued to show a protective effect. However, there were far fewer
occurrences of cryptococcal disease overall among those who were
CrAg-negative at baseline, compared to those who were CrAg-
positive.
We found no trials that reported on resistance of Cryptococcus
isolates, and this is an important gap in our understanding of the
adverse effects of antifungal prophylaxis.
There was some evidence that antifungal prophylaxis may increase
the number of resistant Candida species in surveillance samples;
however, it is unclear if this translates to clinically meaningful
Candida resistance, as no clear effect was demonstrated on the
risk of developing clinically resistant Candida disease. However,
the certainty of the evidence contributing to these analyses was
low, making it difficult to draw firm conclusions on the impact of
antifungal prophylaxis on Candida resistance.
The data on adverse events from these trials were graded as low
quality, and as a result, we should also interpret the finding of no
clear difference between treatment arms with caution. However,
moderate-quality evidence suggested that treatment discontinu-
ation did not clearly differ between study arms, suggesting that
adverse events may in fact not differ between the groups.
Certainty of the evidence
We assessed the certainty of the evidence using the GRADE ap-
proach and presented our findings in the Summary of findings
for the main comparison. Three of the included studies were de-
signed as open label studies. We did not consider this biased the
outcomes measured, as our primary outcome, and most of the
secondary outcomes, were objectively measured. Certainty ranged
from moderate to low across all the reported outcomes. Reasons
for downgrading included: the majority of participants not receiv-
ing the current standard of care relating to type of ART, and time
from diagnosis to initiation, indirectness related to the subjective
assessment of mortality due to cryptococcal disease, few events,
unclear grading of serious adverse events, and unexplained sub-
stantial heterogeneity related to the assessment of adverse events.
Many of the trials we found were older and less relevant to cur-
rent HIV care; we considered this in our approach to GRADEing
indirectness.
Potential biases in the review process
We minimized biases in the conduct of this review by adhering
to the standard methodology described in Cochrane Handbook for
Systematic reviews of Interventions.We conducted a comprehensive
literature search with no language restrictions. Two authors inde-
pendently scanned the search results for potentially eligible stud-
ies. Two review authors independently assessed full-text articles of
potentially eligible trials, and two review authors independently
extracted data from the nine included trials.
We recognized that there were limitations and potential biases in
measuring mortality due to cryptococcal disease, due to the risk of
misdiagnosis. However, we chose to include this outcome to give
a better reflection of the effect of the intervention on cryptococcal
disease. We took this into account in our assessment of the cer-
tainty of the evidence.
Resistance to fluconazole is one of the main concerns and crit-
icisms of antifungal prophylaxis, but microbiological resistance
detected in surveillance cultures did not necessarily translate to
clinical disease; however, the review would have been somewhat
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incomplete if we did not present all the evidence that was available
on this issue. Again, this was taken into account in our assessment
of the certainty of the evidence.
We further amended our inclusion criteria to include studies with
co-interventions. We minimized the confounding effect of these
co-interventions by only including trials with outcomes where the
co-interventions were considered to haveminimal or no impact on
the outcome being measured. For example, Hakim 2017 reported
a reduction in all-cause mortality; however, there were important
co-interventions that would have had an effect on mortality, so
these data were not included in the analysis for this outcome.
These differences are detailed in the Differences between protocol
and review section.
Agreements and disagreements with other
studies or reviews
The findings from this review were consistent with those of pre-
vious published reviews, which both showed that antifungal pro-
phylaxis may have made little or no difference to all-cause mor-
tality, but reduced the occurrence of cryptococcal disease (Chang
2005; Ssekitoleko 2013). However, the findings from this review
are more relevant to current HIV populations.
One study included in the Chang 2005 review did not meet our
inclusion criteria. We also included two studies published after
the Chang 2005 review (Hakim 2017; Parkes-Ratanshi 2011).
Furthermore, we considered outcomes related to resistance in tri-
als looking at prevention of Candida infection, which were not
included in the Chang 2005 review (Goldman 2005; Revankar
1998; Schuman 1997) .
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Primary prophylaxis with either fluconazole or itraconazole prob-
ably reduces the risk of developing cryptococcal disease. Prophy-
laxis also probably reduces the risk of death due to cryptococcal
disease, however, this may not have translated to a reduction in
all-cause mortality in the trials identified. Clinicians and policy
makers will have to consider the benefit of providing antifungal
prophylaxis in the context of cryptococcal disease prevalence, cost,
consistent drug supply, and the availability of cryptococcal antigen
(CrAg) screening in their setting. Antifungal primary prophylaxis
could be considered a part of differentiated packages of care for
those who are diagnosed late with low cluster of differentiation 4
(CD4) cell counts, and those at risk of cryptococcal disease, par-
ticularly where CrAg screening is unavailable.
Implications for research
The authors do not believe that further research is required to
show the efficacy of primary antifungal prophylaxis in reducing
the occurrence of cryptococcal disease, particularly among patients
where CrAg status is unknown. The cost-benefit of providing an-
tifungal prophylaxis to CrAg-negative patients remains an area of
debate, due to the low occurrence of cryptococcal disease in this
group. Further analyses of the cost effectiveness and feasibility of
implementing this intervention in different settings are needed,
as well as comparisons between the primary prophylaxis strategy
and the strategy of CrAg screening plus pre-emptive antifungal
therapy for those who screened positive.
A C K N OW L E D G E M E N T S
The Academic Editor of this review was Professor Mical Paul.
We thank theCochrane InfectiousDiseaseGroup for their support
and help in streamlining the review process and Paul Garner for
his help as Co-ordinating Editor.
We thank Vittoria Lutje and Joy Oliver for helping with the search
strategy. We want to thank Marcel Kitenge for his contribution
and assistance with conference and additional searches.
Ajibola Awotiwon, Ingrid Eshun-Wilson, and Samuel Johnson
were supported by the Effective Health Care Research Consor-
tium. This Consortium and the CIDG editorial base is funded
by UK aid from the UK Government for the benefit of low- and
middle-income countries (Grant: 5242). The views expressed in
this publication do not necessarily reflect UK government policy.
SJ was supported by a funding agreement from Cochrane CRG
support programme (Cochrane UK).
GraemeMeintjes was supported by theWellcome Trust (098316),
and the South African Research Chairs Initiative of the Depart-
ment of Science and Technology and National Research Founda-
tion (NRF) of South Africa (Grant No 64787).
18Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
R E F E R E N C E S
References to studies included in this review
Chariyalertsak 2002 {published data only}
Chariyalertsak S, Supparatpinyo K, Sirisanthana T, Nelson
KE. A controlled trial of itraconazole as primary prophylaxis
for systemic fungal infections in patients with advanced
human immunodeficiency virus infection in Thailand.
Clinical Infectious Diseases 2002;34(2):277–84. PUBMED:
11740718]
Chetchotisakd 2004 {published data only}
Chetchotisakd P, Sungkanuparph S, Thinkhamrop
B, Mootsikapun P, Boonyaprawit P. A multicentre,
randomized, double-blind, placebo-controlled trial of
primary cryptococcal meningitis prophylaxis in HIV-
infected patients with severe immune deficiency. HIV
Medicine 2004;5(3):140–3. PUBMED: 15139978]
Goldman 2005 {published data only}
∗ Goldman M, Cloud GA, Wade KD, Reboli AC,
Fichtenbaum CJ, Hafner R, et al. A randomized study
of the use of fluconazole in continuous versus episodic
therapy in patients with advanced HIV infection and a
history of oropharyngeal candidiasis: AIDS Clinical Trials
Group Study 323/Mycoses Study Group Study 40. Clinical
Infectious Diseases 2005;41(10):1473–80.
NCT00000951. A study to compare the use of fluconazole
as continuous therapy versus periodic therapy in HIV-
positive patients with recurrent thrush [A Phase IV
randomized study of the use of fluconazole as chronic
suppressive therapy versus episodic therapy in HIV
positive subjects with recurrent oropharyngeal candidiasis].
clinicaltrials.gov/ct2/show/NCT00000951 (first posted 31
August 2001).
Hakim 2017 {published data only}
∗ Hakim J, Musiime V, Szubert AJ, Mallewa J, Siika A,
Agutu C, et al. Enhanced prophylaxis plus antiretroviral
therapy for advanced HIV infection in Africa. New England
Journal of Medicine 2017;377(3):233–45.
ISRCTN43622374. Reduction of early mortality in HIV-
infected African adults and children starting antiretroviral
therapy [Reduction of Early mortALITY in HIV–infected
African adults and children starting antiretroviral
therapy: a randomised controlled trial]. isrctn.com/
ISRCTN43622374 (first received 28 September 2011).
McKinsey 1999 {published data only}
Goldman M, Cloud GA, Smedema M, LeMonte A,
Connolly P, McKinsey DS, et al. Does long-term
itraconazole prophylaxis result in in vitro azole resistance
in mucosal Candida albicans isolates from persons with
advanced human immunodeficiency virus infection? The
National Institute of Allergy and Infectious DiseasesMycoses
study group. Antimicrobial Agents and Chemotherapy 2000;
44(6):1585–7. PUBMED: 10817713]
Le Monte AM, Goldman M, Smedema ML, Connolly PA,
McKinsey DS, Cloud GA, et al. DNA fingerprinting of
serial Candida albicans isolates obtained during itraconazole
prophylaxis in patients with AIDS.Medical Mycology 2001;
39(2):207–13. PUBMED: 11346270]
∗ McKinsey DS, Wheat LJ, Cloud GA, Pierce M, Black
JR, Bamberger DM, et al. Itraconazole prophylaxis
for fungal infections in patients with advanced human
immunodeficiency virus infection: randomized, placebo-
controlled, double-blind study. National Institute of Allergy
and Infectious Diseases Mycoses Study Group. Clinical
Infectious Diseases 1999;28(5):1049–56. PUBMED:
10452633]
Parkes-Ratanshi 2011 {published data only}
ISRCTN76481529. Primary prevention of invasive
cryptococcal disease using fluconazole prophylaxis in
Human Immunodeficiency Virus (HIV) infected Ugandans.
isrctn.com/ISRCTN76481529 (first received 18 May
2001).
Parkes-Ratanshi R, Wakeham K, Kamali A, Levin J,
Coutinho A, Whitworth J, et al. Successful primary
prevention of cryptococcal disease using fluconazole
prophylaxis in HIV-infected Ugandan adults (cryptopro):
o26. HIV Medicine 2009;10:8–9.
∗ Parkes-Ratanshi R, Wakeham K, Levin J, Namusoke
D, Whitworth J, Coutinho A, et al. Primary prophylaxis
of cryptococcal disease with fluconazole in HIV-positive
Ugandan adults: a double-blind, randomised, placebo-
controlled trial. Lancet Infectious Diseases 2011;11(12):
933–41. PUBMED: 21982529]
Revankar 1998 {published data only}
Revankar SG, Kirkpatrick WR, McAtee RK, Dib OP,
Fothergill AW, Redding SW, et al. A randomized trial of
continuous or intermittent therapy with fluconazole for
oropharyngeal candidiasis in HIV-infected patients: clinical
outcomes and development of fluconazole resistance.
American Journal of Medicine 1998;1:7–11.
Schuman 1997 {published data only}
∗ Schuman P, Capps L, Peng G, Vazquez J, el-Sadr W,
Goldman AI, et al. Weekly fluconazole for the prevention
of mucosal candidiasis in women with HIV infection. A
randomized, double-blind, placebo-controlled trial. Terry
Beirn Community Programs for Clinical Research on AIDS.
Annals of Internal Medicine 1997;126(9):689–96.
Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P,
Holloway W, et al. Evolution of antifungal susceptibility
among Candida species isolates recovered from human
immunodeficiency virus-infected women receiving
fluconazole prophylaxis. Clinical Infectious Diseases 2001;33
(7):1069–75.
Vazquez JA, Sobel JD, Peng G, Steele-Moore L, Schuman
P, Holloway W, et al. Evolution of vaginal Candida species
recovered from human immunodeficiency virus-infected
women receiving fluconazole prophylaxis: the emergence of
Candida glabrata? Terry Beirn Community Programs for
Clinical Research in AIDS (CPCRA). Clinical Infectious
Diseases 1999;28(5):1025–31.
19Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Smith 2001 {published data only}
Smith DE, Bell J, Johnson M, Youle M, Gazzard B,
Tchamouroff S, et al. A randomized, double-blind,
placebo-controlled study of itraconazole capsules for the
prevention of deep fungal infections in immunodeficient
patients with HIV infection. HIV Medicine 2001;2(2):
78–83. PUBMED: 11737382]
References to studies excluded from this review
Anonymous 1995 {published data only}
Anonymous. Fluconazole may have edge in preventing
infections. AIDS Alert 1995;10(5):67–8.
Anonymous 2001 {published data only}
Anonymous. Antifungal drug fluconazole found to be
effective in preventing thrush in people who are HIV
positive. AHRQ Research Activities 2001;250:15.
Apisarnthanarak 2008a {published data only}
Apisarnthanarak A, Mundy LM. The impact of primary
prophylaxis for cryptococcosis on fluconazole resistance in
Candida species. Journal of Acquired Immune Deficiency
Syndromes 2008;47(5):644–5.
Chaiwarith 2011 {published data only}
Chaiwarith R, Fakthongyoo A, Praparattanapan J, Boonmee
D, Sirisanthana T, Supparatpinyo K. Itraconazole vs
fluconazole as a primary prophylaxis for fungal infections
in HIV-infected patients in Thailand. Curr HIV Research
2011;9(5):334–8.
Chaiwarith 2013 {published data only}
Chaiwarith R, Praparattanapan J, Nuntachit N,
Kotarathitithum W, Supparatpinyo K. Discontinuation
of primary and secondary prophylaxis for opportunistic
infections in HIV-infected patients who had CD4+ cell
count 3 but undetectable plasma HIV-1 RNA: an open-
label randomized controlled trial. AIDS Patient Care and
STDs 2013;27(2):71–6.
Geletko 1996 {published data only}
Geletko SM, Segarra M, Mayer KH, Fiore TC, Bettencourt
FA, Flanigan TP, et al. Electronic compliance assessment of
antifungal prophylaxis for human immunodeficiency virus-
infected women. Antimicrobial Agents and Chemotherapy
1996;40(6):1338–41.
Havlir 1998 {published data only}
Havlir DV, Dube MP, McCutchan JA, Forthal DN, Kemper
CA, Dunne MW, et al. Prophylaxis with weekly versus daily
fluconazole for fungal infections in patients with AIDS.
Clinical Infectious Diseases 1998;27(6):1369–75.
Jüst-Nubling 1991 {published data only}
Jüst-Nubling G, Gentschew G, Meissner K, Odewald J,
Staszewski S, Helm EB, et al. Fluconazole prophylaxis
of recurrent oral candidiasis in HIV-positive patients.
European Journal of Clinical Microbiology & Infectious
Diseases 1991;10(11):917–21.
Manfredi 1997 {published data only}
Manfredi R, Mastroianni A, Coronado OV, Chiodo F.
Fluconazole as prophylaxis against fungal infection in
patients with advanced HIV infection. Archives of Internal
Medicine 1997;157(1):64–9.
Manosuthi 2005 {published data only}
Manosuthi W, Chumpathat N, Chaovavanich A,
Sungkanuparph S. Safety and tolerability of nevirapine-
based antiretroviral therapy in HIV-infected patients
receiving fluconazole for cryptococcal prophylaxis: a
retrospective cohort study. BMC Infect Diseases 2005;5:67.
Manosuthi 2006 {published data only}
Manosuthi W, Sungkanuparph S, Thongyen S, Chumpathat
N, Eampokalap B, Thawornwan U, et al. Antifungal
susceptibilities of Cryptococcus neoformans cerebrospinal
fluid isolates and clinical outcomes of cryptococcal
meningitis in HIV-infected patients with/without
fluconazole prophylaxis. Journal of the Medical Association of
Thailand 2006;89(6):795–802.
Mfinanga 2015 {published data only}
Mfinanga S, Chanda D, Kivuyo SL, Guinness L, Bottomley
C, Simms V, et al. Cryptococcal meningitis screening and
community-based early adherence support in people with
advanced HIV infection starting antiretroviral therapy
in Tanzania and Zambia: an open-label, randomised
controlled trial. Lancet 2015;385(9983):2173–82.
Micol 2010 {published data only}
Micol R, Tajahmady A, Lortholary O, Balkan S, Quillet C,
Dousset JP, et al. Cost-effectiveness of primary prophylaxis
of AIDS associated cryptococcosis in Cambodia. PLoS One
2010;5(11):e13856.
Mylonakis 1998 {published data only}
Mylonakis E, Flanigan TP. Editorial response: Antifungal
prophylaxis with weekly fluconazole for patients with AIDS.
Clinical Infectious Diseases 1998;27(6):1376–8.
Penzak 1998 {published data only}
Penzak SR, Gubbins PO. Preventing and treating azole-
resistant oropharyngeal candidiasis in HIV-infected
patients. American Journal of Health-System Pharmacy 1998;
55(3):279–83.
Powderly 1995 {published data only}
Powderly WG, Finkelstein D, Feinberg J, Frame P, He W,
van der Horst C, et al. A randomised trial comparing
fluconazole with clotrimazole troches for the prevention
of fungal infections in patients with advanced human
immunodeficiency virus infection. NIAID AIDS Clinical
Trials Group. New England Journal of Medicine 1995;332
(11):700–5.
Singh 1996 {published data only}
Singh N, Barnish MJ, Berman S, Bender B, Wagener
MM, Rinaldi MG, et al. Low-dose fluconazole as primary
prophylaxis for cryptococcal infection in AIDS patients
with CD4 cell counts of ≤ 100/mm³: demonstration of
efficacy in a positive, multicenter trial. Clinical Infectious
Diseases 1996;23(6):1282–6.
Stevens 1991 {published data only}
Stevens DA, Greene SI, Lang OS. Thrush can be prevented
in patients with acquired immunodeficiency syndrome and
20Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
the acquired immunodeficiency syndrome-related complex.
Randomized, double-blind, placebo-controlled study of
100-mg oral fluconazole daily. Archives of Internal Medicine
1991;151(12):2458–64. PUBMED: 1747004]
Svoboda 1995 {published data only}
Svoboda J. Prophylaxis of opportunistic infections in HIV
infection. Journal of Community Health 1995;20(2):203–7.
Thurey 2008 {published data only}
Thurey J, Molyneux E. Evidence behind the WHO
guidelines: Hospital Care for Children: the usefulness of
azole prophylaxis against cryptococcal meningitis in HIV-
positive children. Journal of Tropical Pediatrics 2008;54(6):
361–3.
Wakeham 2010 {published data only}
Wakeham K, Parkes-Ratanshi R,Watson V, Ggayi AB, Khoo
S, Lalloo DG. Co-administration of fluconazole increases
nevirapine concentrations in HIV-infected Ugandans.
Journal of Antimicrobial Chemotherapy 2010;65(2):316–9.
White 1993 {published data only}
White MH. Antifungal prophylaxis. Current Opinion in
Infectious Diseases 1993;6(6):737–839.
References to studies awaiting assessment
Anonymous 1998 {published data only}
Anonymous. Preventing mucosal candidiasis in HIV-
infected women. Emergency Medicine 1998;30(2):112–5.
Smith 1999 {published data only}
Smith D, Midgley J, Gazzard B. A randomised, double-
blind study of itraconazole versus placebo in the treatment
and prevention of oral or oesophageal candidosis in patients
with HIV infection. International Journal of Clinical Practice
1999;53(5):349–52. PUBMED: 10695098]
Additional references
Apisarnthanarak 2008b
Apisarnthanarak A, Jirayasethpong T, Sa-nguansilp C,
Thongprapai H, Kittihanukul C, Kamudamas A, et al.
Antiretroviral drug resistance among antiretroviral-naive
persons with recent HIV infection in Thailand. HIV
Medicine 2008;9(5):322–5. [PUBMED: 18400079]
Brion 2007
Brion LP, Uko SE, Goldman DL. Risk of resistance
associated with fluconazole prophylaxis: systematic review.
Journal of Infection 2007;54(6):521–9. [PUBMED:
17239952]
CDC 2017
Panel on Opportunistic Infections in HIV-Infected Adults,
Adolescents. Guidelines for the prevention and treatment
of opportunistic infections in HIV-infected adults and
adolescents: recommendations from the Centers for Disease
Control and Prevention, the National Institutes of Health,
and the HIV Medicine Association of the Infectious
Diseases Society of America. Available at aidsinfo.nih.gov/
contentfiles/lvguidelines/adult oi.pdf (accessed 3 Sept
2017).
Cheong 2013
Cheong JW, McCormack J. Fluconazole resistance in
cryptococcal disease: emerging or intrinsic?. Medical
Mycology 2013;51(3):261–9. [PUBMED: 22989195]
DAIDS 2014
DAIDS Grading Table Working Group. Division of
AIDS (DAIDS) Table for Grading the Severity of Adult
and Pediatric Adverse Events. Version 2.0. Division
of AIDS, National Institute of Allergy and Infectious
Diseases, National Institutes of Health, US Department
of Health and Human Services. November 2014.
Available from rsc.tech-res.com/docs/default-source/safety/
daids ae grading table v2 nov2014.pdf.
GRADEpro GDT [Computer program]
McMaster University (developed by Evidence Prime).
GRADEpro GDT. Version accessed 6 August 2017.
Hamilton (ON): McMaster University (developed by
Evidence Prime), 2015.
Higgins 2011
Higgins JPT, Green S, editor(s). Cochrane Handbook
for Systematic Reviews of Interventions Version 5.1.0
(updated March 2011). The Cochrane Collaboration,
2011. Available from handbook.cochrane.org.
HIV drug interactions 2018
Liverpool HIV drug interactions. HIV drug interaction
checker. www.hiv-druginteractions.org/checker (accessed
22 May 2018).
Jarvis 2010
Jarvis JN, Meintjes G, Williams A, Brown Y, Crede T,
Harrison TS. Adult meningitis in a setting of high HIV and
TB prevalence: findings from 4961 suspected cases. BMC
Infectious Diseases 2010;10:67. [PUBMED: 20230635]
Kambugu 2008
Kambugu A, Meya DB, Rhein J, O’Brien M, Janoff EN,
Ronald AR, et al. Outcomes of cryptococcal meningitis in
Uganda before and after the availability of highly active
antiretroviral therapy. Clinical Infectious Diseases 2008;46
(11):1694–701. [PUBMED: 18433339]
Kontoyiannis 2002
Kontoyiannis DP, Lewis RE. Antifungal drug resistance
of pathogenic fungi. Lancet 2002;359(9312):1135–44.
[PUBMED: 11943280]
Lessells 2011
Lessells RJ, Mutevedzi PC, Heller T, Newell ML. Poor long-
term outcomes for cryptococcal meningitis in rural South
Africa. South African Medical Journal 2011;101(4):251–2.
[PUBMED: 21786729]
McLachlan 1996
McLachlan AJ, Tett SE. Pharmacokinetics of fluconazole
in people with HIV infection: a population analysis.
British Journal of Clinical Pharmacology 1996;41(4):291–8.
[PUBMED: 8730974]
Mirza 2003
Mirza SA, Phelan M, Rimland D, Graviss E, Hamill
R, Brandt ME, et al. The changing epidemiology of
21Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
cryptococcosis: an update from population-based active
surveillance in 2 large metropolitan areas, 1992-2000.
Clinical Infectious Diseases 2003;36(6):789–94. [PUBMED:
12627365]
Pierard 2000
Pierard GE, Arrese JE, Pierard-Franchimont C. Itraconazole.
Expert Opinion on Pharmacotherapy 2000;1(2):287–304.
Pound 2011
Pound MW, Townsend ML, Dimondi V, Wilson D,
Drew RH. Overview of treatment options for invasive
fungal infections. Medical Mycology 2011;49(6):561–80.
[PUBMED: 21366509]
Rajasingham 2017
Rajasingham R, Smith RM, Park BJ, Jarvis JN, Govender
NP, Chiller TM, et al. Global burden of disease of HIV-
associated cryptococcal meningitis: an updated analysis.
Lancet Infectious Diseases 2017;17(8):873–81. [PUBMED:
28483415]
RevMan 2014 [Computer program]
Nordic Cochrane Centre, The Cochrane Collaboration.
Review Manager 5 (RevMan 5). Version 5.3. Copenhagen:
Nordic Cochrane Centre, The Cochrane Collaboration,
2014.
Rhein 2016
Rhein J, Morawski BM, Hullsiek K, Nabeta H, Kiggundu
R, Tugume L, et al. Efficacy of adjunctive sertraline for the
treatment of HIV-associated cryptococcal meningitis: an
open-label dose-ranging study. Lancet Infectious Diseases
2016;16(7):809–18.
Skolnik 2017
Skolnik K, Huston S, Mody CH. Cryptococcal lung
infections. Clinical Chest Medicine 2017;38:451–64.
Ssekitoleko 2013
Ssekitoleko R, Kamya MR, Reingold AL. Primary
prophylaxis for cryptococcal meningitis and impact on
mortality in HIV: a systematic review and meta-analysis.
Future Virology 2013;8(9):917–30. [PUBMED: 24368930]
Tenforde 2017
Tenforde MW, Mokomane M, Leeme T, Patel RKK,
Lekwape N, Ramodimoosi C, et al. Advanced HIV disease
in Botswana following successful antiretroviral therapy
rollout: incidence of and temporal trends in cryptococcal
meningitis. Clinical Infectious Diseases 2017;65(5):779–86.
[PUBMED: 28505328]
Wall 2014
Wall EC, Everett DB, Mukaka M, Bar-Zeev N, Feasey N,
Jahn A, et al. Bacterial meningitis in Malawian adults,
adolescents, and children during the era of antiretroviral
scale-up and Haemophilus influenzae type B vaccination,
2000-2012. Clinical Infectious Diseases 2014;58(10):
e137–45.
WHO 2011
World Health Organization. Rapid advice: diagnosis,
prevention and management of cryptococcal disease in
HIV-infected adults, adolescents and children: World
Health Organization. December 2011. Available
from apps.who.int/iris/bitstream/handle/10665/44786/
9789241502979 eng.pdf?sequence=1.
WHO 2016
World Health Organization. Consolidated guidelines on
the use of antiretroviral drugs for treating and preventing
HIV infection: recommendations for a public health
approach. 2nd edition. World Health Organization. 2016.
Available from apps.who.int/iris/bitstream/handle/10665/
208825/9789241549684 eng.pdf?sequence=1.
Williamson 2017
Williamson PR, Jarvis JN, Panackal AA, Fisher MC, Molloy
SF, Loyse A, et al. Cryptococcal meningitis: epidemiology,
immunology, diagnosis and therapy. Nature Reviews.
Neurology 2017;13(1):13–24. [PUBMED: 27886201]
References to other published versions of this review
Chang 2004
Chang LW, Phipps WT, Rutherford GW. Antifungal
interventions for the primary prevention of cryptococcal
disease in adults with HIV. Cochrane Database of
Systematic Reviews 2004, Issue 4. DOI: 10.1002/
14651858.CD004773
Chang 2005
Chang LW, Phipps WT, Kennedy GE, Rutherford GW.
Antifungal interventions for the primary prevention of
cryptococcal disease in adults with HIV. Cochrane Database
of Systematic Reviews 2005, Issue 3. DOI: 10.1002/
14651858.CD004773.pub2
∗ Indicates the major publication for the study
22Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Chariyalertsak 2002
Methods Study design: randomized controlled trial (RCT)
Participants Inclusion criteria: 18 to 60 years, documented HIV infection, Karnofsky score of > 70
(normal activity possible with effort), absolute CD4 lymphocyte count of < 200 cells/
µL, and residence in the Chiang Mai area
Exclusion criteria: history of systemic fungal infections, use of systemic antifungal
therapy within 2 weeks before study entry, history of active tuberculosis, pregnancy or
breastfeeding, a history of intolerance to triazole compounds, failure to use a medically
approved and effective method of birth control, inability to take oral medications, use of
a medication with a known interaction with itraconazole, and serum aminotransferase
levels at > 5 times the upper limit of normal
Number randomized: 129
Descriptive baseline data:
• Age [mean (range) years]: itraconazole 33.4 (22 to 51); placebo 33.3 (23 to 58)
• Sex [% male]: itraconazole 38%; placebo 38%
• CD4 count [median cells/µL]: itraconazole (60); placebo (73)
• ART regimen provided: non-triple
• Time to ART: not reported
• CrAg status: not reported
• % on ART: 6.2%
• Duration of follow-up [median (range) weeks]: itraconazole [40 (6 to 104)];
placebo [35 (5 to 104)
Dropouts during study period: 0
Interventions • Itraconazole 200 mg daily
• Placebo
Outcomes • All-cause mortality at 104 weeks
• Cryptococcal disease incidence over 104 weeks
• Adherence: reported as a percentage above a defined threshold - by calculating
the proportion of doses reportedly missed at each visit and using that value to estimate
the number of days each week that study drugs were taken.
• Treatment discontinuation over 104 weeks
• Adverse events over 104 weeks
Notes Country: Thailand
Setting: hospital
Dates: March 1998 to February 2000 (recruitment)
Funding: Funded by Janssen Pharmaceuticals
Others: Study was stopped in March 2000 after the first patient completed 104 weeks
of follow-up, when an interim analysis showed significant difference in the occurrence
of systemic fungal infections between the two groups
Risk of bias
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Chariyalertsak 2002 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk The patients were randomly assigned to re-
ceive itraconazole or placebo in a 1:1 ra-
tio. Randomization was performed by the
drug manufacturer (Janssen Pharmaceuti-
cal) with a computerized randomization list
based on a block size of 6
Allocation concealment (selection bias) Low risk The medication was packaged in sequen-
tially numbered boxes that were dispensed
to successive patients
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “A prospective, randomized, placebo-con-
trolled, double-blind study was conducted
to compare the safety and efficacy of itra-
conazole (200 mg per day) with that of
placebo.”
Placebo was identical in appearance to the
study drug
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study was described as double-blind. The
authors did not explicitly state that the out-
come assessors were blinded. However, the
outcomes we assessed in this review were
mostly objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk No participants lost to follow-up.
Selective reporting (reporting bias) Low risk No protocol available, however, no sugges-
tion of selective reporting seen
Other bias Unclear risk Grant received from Janssen Pharmaceuti-
cals; Janssen also randomized participants.
No information on specific conflicts of in-
terests provided
Chetchotisakd 2004
Methods Study design: RCT
Participants Inclusion criteria: adult patients (> 14 years old) with documented HIV infection and
CD4 counts < 100 cells/µL
Exclusion criteria: systemic fungal infection, allergy or intolerance to fluconazole, liver
enzymes > 5 times the normal limit, positive serum cryptococcal antigen, and pregnancy
and lactation in women
Number randomized: 90
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Chetchotisakd 2004 (Continued)
Descriptive baseline data:
• Age [mean (range) years]: fluconazole 33.0 (25 to 46); placebo 32.2 (20 to 53)
• Sex [% male]: fluconazole 70%; placebo 61%
• CD4 count [median cells/µL]: fluconazole (17.2); placebo (23.7)
• CD4 count [mean (range) cells/µL]: fluconazole 29.1 (1.3 to 97.8); placebo 31.2
(1.4 to 96)
• ART regimen provided: non-triple
• Time to ART: not reported
• CrAg status: CrAG-negative: 90/90
• % on ART: 6.7%
• Duration of follow-up [median (range) weeks]: fluconazole [152 (1 to 554)];
placebo [136 (1 to 540)]
Dropouts during study period: not reported
Interventions • Fluconazole 400 mg weekly
• Placebo
Outcomes • All-cause mortality over 152.5 and 136.5 days in the fluconazole and placebo
groups respectively
• Cryptococcal disease occurrence over 152.5 and 136.5 days in the fluconazole
and placebo groups respectively
• Cryptococcal specific mortality over 152.5 and 136.5 days in the fluconazole
and placebo groups respectively
• Severe adverse events over 152.5 and 136.5 days in the fluconazole and placebo
groups respectively
Notes Location: Thailand
Setting: hospital
Dates: February 2000 to August 2001 (recruitment)
Funding: not reported
Others: study was terminated because of the national policy that fluconazole should be
used in practice
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No method recorded
Allocation concealment (selection bias) Unclear risk No method recorded
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “Double-blind” patients received placebo or study medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study was described as double-blind. The authors did not ex-
plicitly state that the outcome assessors were blinded. However,
the outcomes we assessed in this review were mostly objective
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Chetchotisakd 2004 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up and dropout rates not recorded
Selective reporting (reporting bias) Unclear risk Loss to follow-up, dropout rates, and adverse events not reported
in detail (“No serious adverse reaction related to medication was
seen during the study”)
Other bias Unclear risk No information provided on conflicts of interest
Goldman 2005
Methods Study design: open label RCT
Participants Inclusion criteria: documentation of HIV infection, a CD4+ T cell count of less than
or equal to 150 cells/mm³within 30 days before study entry, age over 13, weight > 40 kg,
experienced one episode of oesophageal candidiasis in 6 months before randomization
Exclusion criteria: Pregnant, prior resistant Candida infection, azole allergy or intoler-
ance, development of 3 episodes of OPC within 12 weeks before study entry, history of
EC, need for systemic antifungal therapy, receipt of 11months of continuous systemic or
oral topical antifungal therapy within the past 3 months, severe liver disease, treated for
oppurtunistic infection 14 days prior to randomization, subjects receiving medications
contraindicated with fluconazole
Number randomized: 829
Descriptive baseline data:
• Age [median (range) years]: fluconazole-continuous therapy 38 (21 to 71);
fluconazole-episodic 38 (19 to 67); combined 38 (19 to 71)
• Sex [% male]: fluconazole-continuous therapy 81%; fluconazole-episodic 83%;
combined 82%
• CD4 count [median (range) cells/µL]: fluconazole-continuous therapy 52 (0 to
250); fluconazole-episodic 50 (0 to 209); combined 50 (0 to 250)
• ART regimen provided: non-triple
• Time to ART: not reported
• CrAg status: not reported
• % on ART: 82%
• Duration of follow-up [median (range) months]: 24 (< 1 to 44)
Dropouts during study period: fluconazole-continuous therapy 13%; fluconazole-
episodic 8.9%; combined 11%
Interventions • Fluconazole 200 mg three times per week
• Episode driven fluconazole treatment for Candida infections
Outcomes • All-cause mortality over a median duration of 24 months follow-up
• Cryptococcal disease incidence over a median duration of 24 months follow-up
• Adverse events over a median duration of 24 months follow-up
Notes Location: multi-centre - USA
Setting: hospitals
Dates: May 1997 to April 2000 (recruitment)
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Goldman 2005 (Continued)
Funding: Trial was funded by the National Institute of Allergy and Infectious Diseases,
National Institutes of Health and Pfizer
Others: Defnition of clinically resistant Candida infection:
“A subject was considered to have an fluconazole resistant infection if (1) signs or symp-
toms of oesophageal candidiasis (EC) worsened after 7 days of therapy and either en-
doscopically confirmed EC or worsening oropharyngeal candidiasis (OPC) occurred,
accompanied by oesophageal symptoms; (2) OPC remained after 14 days of therapy for
EC; or (3) OPC or confirmed EC was present after 21 days of therapy”
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Sequence generation not described.
“Eligible subjects were randomised at a ratio of 1:1 to
undergo 1 of 2 different management strategies”
Allocation concealment (selection bias) Unclear risk Allocation concealment not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Open label, outcomes measured not prone to perfor-
mance bias.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Open label trial so blinding of clinical assessors not
possible. No blinding of laboratory staff assessed
Incomplete outcome data (attrition bias)
All outcomes
Low risk Reasons for treatment discontinuation or attrition ad-
dressed in comprehensive flow diagram
184/416 in episodic arm prematurely discontinued
randomized strategy
205/413 in continuous armprematurely discontinued
randomized strategy
Attrition balanced between arms - majority exited due
to non-compliance (balanced between arms)
Selective reporting (reporting bias) Low risk Protocol available. All expected outcomes reported.
Other bias Low risk Funding information reported and conflicts of inter-
ests addressed
Hakim 2017
Methods Study design: open label RCT
Participants Inclusion criteria: HIV-positive adults and children who were 5 years of age or older,
who had not received previous ART, and who had a CD4+ count of fewer than 100 cells
per cubic millimetre
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Hakim 2017 (Continued)
Exclusion criteria: pregnancy or breast-feeding, had received single-dose nevirapine to
prevent mother to-child transmission of HIV, or had any contraindications to the trial
drugs
Number randomized: 1805
Descriptive baseline data:
• Age [median (range) years]: Standard prophylaxis 36 (5 to 78); Enhanced
prophylaxis 36 (6 to 71); All patients 36 (5-78)
• Sex [% male]: Standard prophylaxis 53.8%; Enhanced prophylaxis 52.6%; All
patients 53.2%
• CD4 count [median (IQR) cells/mm³]: Standard prophylaxis 36 (16 to 60);
Enhanced prophylaxis 38 (16 to 64); All patients 37 (16 to 63)
• ART regimen provided: triple
• Time to ART: 5 days (median)
• CrAg status: CrAG-positive: 133/1781
• % on ART: Standard prophylaxis (82%); Enhanced prophylaxis (87%)
• Duration of follow-up (weeks): 48
Dropouts during study period: 3.1%: Standard prophylaxis (24); Enhanced prophy-
laxis (18)
Interventions • Enhanced prophylaxis, which consisted of a single dose (400 mg) of albendazole,
5 days of azithromycin (500 mg once daily), 12 weeks of fluconazole (100 mg once
daily), and 12 weeks of a fixed-dose combination of trimethoprim-sulfamethoxazole
(160 mg of trimethoprim and 800 mg of sulfamethoxazole), isoniazid (300 mg), and
pyridoxine (25 mg) as a scored once-daily tablet (total, three tablets per day for 1 to 5
days, then two pills per day for 12 weeks). Doses were halved for children younger than
13 years of age, except for albendazole.
• Standard prophylaxis which consisted of trimethoprim-sulfamethoxazole alone.
Outcomes • Cryptococcal disease occurrence over 48 weeks
• Cryptococcal specific mortality at 48 weeks
Notes Location: multicentre; Uganda, Zimbabwe, Malawi, and Kenya
Setting: Urban and peri-urban centres
Dates: June 2013 to April 2015 (recruitment)
Funding: supported by the Joint Global Health Trials Scheme of the Medical Research
Council (MRC), the U.K. Department for International Development, the Wellcome
Trust, and the PENTA Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “computer generated sequential randomisation list
with variably sized permuted blocks was prepared by
the trial statistician and incorporated securely into the
online trial database.”
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Hakim 2017 (Continued)
Allocation concealment (selection bias) Low risk “The list was concealed until eligibility was confirmed
by staff members at the local centre, who then per-
formed the randomisation”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk “open label”; “ all nurses and physicians were aware of
the trial-group assignments”
Although study was unblinded, this was unlikely to
have an impact on the outcome we extracted from this
study - cryptococcal disease
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Outcome assessment was not blinded - however, diag-
nosis of cryptococcal meningitis is not very subjective
and we did not think this would have introduced bias,
in addition, secondary outcomes were evaluated by a
review board
“An end-point review committeewhosememberswere
unaware of trial-group assignment and trial drugs re-
ceived used protocol defined criteria and grading ta-
bles to adjudicate all the secondary clinical outcomes
that were reported by the trial physicians”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3% were lost to follow up or withdrew consent after
randomization
Selective reporting (reporting bias) Low risk These were not the results of the full study - patients
were also randomized to receive raltegravir and addi-
tional nutrition. However all results relevant to the
antifungal prophylaxis portion of the study were re-
ported. The protocol was available for review
Other bias Low risk Of note, patients also were randomized to receive ral-
tegravir or nutritional supplements, which may have
impacted some of the outcomes, but unlikely to im-
pact diagnosis of cryptococcal meningitis
McKinsey 1999
Methods Study design: RCT
Participants Inclusion criteria: age > 13 years, HIV (western blot or enzyme immunoassay), life
expectancy > 1 year, no life-threatening infection or malignancy other than Kaposi
sarcoma, CD4 < 150, and residence in a city with high prevalence of histoplasmosis
Exclusion criteria: Use of investigational drug in last 1 month, pregnancy or lactation,
failure to use contraception, history of intolerance, unable to take medications orally,
active fungal infection, and use of medication with interaction
Number randomized: 295
Descriptive baseline data:
• Age [median years]: itraconazole 37; placebo 36; total 37
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McKinsey 1999 (Continued)
• Sex [% male]: itraconazole 96%; placebo 96%; total 96%
• CD4 count [median cells/mm³]: itraconazole 57; placebo 63; total 61
• ART regimen provided: non-triple
• Time to ART: not reported
• CrAg status: not reported
• % on ART: itraconazole 65%; placebo 63%; total 64%
• Duration of follow-up [mean (range) months]: 16 (1 to 34)
Dropouts during study period: not reported
Interventions • Itraconazole 200 mg daily
• Placebo
Outcomes • All-cause mortality at 16 months
• Cryptococcal disease incidence over 16 months
• Cryptococcal specific mortality at 16 months
• Candidaspecies antifungal drug resistance over 16 months
• Treatment discontinuation over 16 months
• Adverse events over 16 months
Notes Location: USA
Setting: multi-centre: urban (Kansas, Indianapolis, Nashville, Memphis)
Dates: June 1993 to April 1995 (recruitment)
Funding: The study was supported by the National Institute of Allergy and Infectious
Diseases and the Janssen Research Foundation
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Method of randomization not explicitly stated, although it is
stated that each site had an independent randomization code
“Randomisation was stratified by site, and each site in the study
had an independent randomisation code.”
Allocation concealment (selection bias) Unclear risk Method not reported
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Study was described as double-blind and they received a placebo
capsule, which was identical in appearance to itraconazole
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study was described as double-blind. The authors did not ex-
plicitly state that the outcome assessors were blinded. However,
the outcomes we assessed in this review were mostly objective
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk Loss to follow-up was not reported.
Selective reporting (reporting bias) Low risk All outcomes mentioned in the methods section were reported.
No protocol available
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McKinsey 1999 (Continued)
Other bias Unclear risk Funded by the National Institute of Allergy and Infectious Dis-
eases and by Janssen Research Foundation. No information pro-
vided on role of funding on study design or outcomes assessed
Parkes-Ratanshi 2011
Methods Study design: RCT
Participants Inclusion criteria: ART-naïve adults (> 15 years) with laboratory confirmation of HIV
infection (Murex HIV-1.2.0, Murex Biotech; HIV Uni-form II plus O, Biomerieux;
Cambridge Biotech HIV-1Western blot) and a CD4 count less than 200 cells/µL (FAC-
SCount Becton Dickinson, USA)
Exclusion criteria: serum cryptococcal antigen (CrAg; Remel, Lexana, USA) titre > 1:
8 on 2 occasions, pregnancy or lactation, liver transaminases (LFT) > 3 x upper limit of
normal (ULN), and moribund patients
Number randomized: 1519
Descriptive baseline data:
• Age [mean (SD) years]: fluconazole 35.9 (9.1); placebo 35.8 (8.8)
• Sex [% male]: fluconazole 38%; placebo 33%
• CD4 count [median (IQR) cells/mm³]: fluconazole 110 (45 to 160); placebo 112
(48 to 157)
• ART regimen provided: triple
• Time to ART: 11 weeks (median; IQR 7 to 17 weeks); fluconazole 82 days;
placebo 87 days
• CrAg status: CrAG-positive:1519/1519
• % on ART: fluconazole 84%; placebo 87%
• Duration of follow-up [median (range) weeks]: fluconazole 59 (27 to 124);
placebo 60 (28 to 123)
Dropouts during study period: fluconazole (4%); placebo (2.5%)
Interventions • Fluconazole 200 mg 3 times per week
• Placebo
Outcomes • All-cause mortality at 60 weeks on placebo and 59 weeks on fluconazole
• Cryptococcal disease occurrence over 60 weeks on placebo and 59 weeks on
fluconazole
• Cryptococcal specific mortality at 60 weeks on placebo and 59 weeks on
fluconazole
• Treatment discontinuation over 60 weeks on placebo and 59 weeks on
fluconazole
• Adverse events over 60 weeks on placebo and 59 weeks on fluconazole
Notes Location: Uganda
Setting: multi-centre - hospitals and clinics
Dates: Sept 2004 to Feb 2008 (recruitment)
Funding: The trial was fundedby theMedical ResearchCouncil,UK, and theRockefeller
Foundation
31Primary antifungal prophylaxis for cryptococcal disease in HIV-positive people (Review)
Copyright © 2018 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The
Cochrane Collaboration.
Parkes-Ratanshi 2011 (Continued)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “An independent statistician prepared a list for 1:1 randomisa-
tion to fluconazole or matching placebo in random permuted
blocks of size 40.”
Allocation concealment (selection bias) Low risk “Trial drug was packaged and labelled by an independent clin-
ician and pharmacist. Participants were allocated to sequen-
tial trial numbers on enrolment and received the corresponding
sealed trial drug pack.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Patients received matching placebo or study medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk “The (EPRC) had access to participants’ files, hospital notes,
verbal autopsy data, and retrospective CrAg results, but were
blind to treatment group.”
Incomplete outcome data (attrition bias)
All outcomes
Low risk 3.3% of participants were lost to follow-up and 1% withdrew
consent
Selective reporting (reporting bias) Low risk Trial was registered on controlled-trials.com
Other bias Low risk “This research was supported by the Medical Research Council,
UK, and the Rockefeller Foundation. Neither had a role in de-
sign, analysis, or writing of this paper.”
Revankar 1998
Methods Study design: open label RCT
Participants Inclusion criteria: HIV-positive patients, CD4 < 350, evidence of active oropharyngeal
candidiasis by potassium hydroxide (KOH) preparation and culture and currently not
taking any azole compound
Exclusion criteria: known hypersensitivity to azole compounds, were unable to take
oral medications, pregnancy, serum alanine aminotransferase/aspartate aminotransferase
ratio more than 10 times normal, serum alkaline phosphatase level more than 5 times
normal, bilirubin level was more than 3 times normal
Number randomized: 62
Descriptive baseline data:
• Age: not reported
• Sex [% male]: not reported
• CD4 count [median (range) cells/mm³]: fluconazole-continuous 43 (4 to 116);
fluconazole-intermittent 23 (4 to 191)
• ART regimen provided: not reported
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Revankar 1998 (Continued)
• Time to ART: not reported
• CrAg status: not reported
• % on ART: not reported
• Duration of follow-up [median (range) months]: fluconazole-continuous 9.3 (3
to 20.5); fluconazole-intermittent 8.4 (3 to 21.5)
Dropouts during study period:fluconazole-continuous (5%); fluconazole-intermittent
(9.5%)
Interventions • Continuous fluconazole 200 mg daily
• Episode driven fluconazole treatment for candidal infections
Outcomes • Candidal resistance over 11 months
Notes Location: USA
Setting: tertiary health centre
Dates: not reported
Funding: the trial was funded by theNational Institute of Dental Research, theNational
Institute of Health for the Frederic C. Bartter General Clinical Research Center and
Pfizer Inc
Others: resistance was defined as a rise in MIC > 16 µg/mL from initial culture, the
emergence of new, resistant (MIC > 16 µg/mL) species any time after the initial culture,
or an increase in the proportion of resistant isolates from 10% to at least 50% in a
species. Patients who had resistant isolates at the initial culture could be considered to
have developed resistance if either of the latter two criteria were present. Microbiological
resistance was defined as simply the presence of resistant isolates (MIC > 16 µg/mL)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was by permuted blocks with a block
size of six
Allocation concealment (selection bias) Unclear risk Allocation concealment not discussed
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Open label trial - assessment of Candida resistance
may be prone to performance bias.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of lab staff not discussed, assessment of Can-
dida resistance may be subjective.
Incomplete outcome data (attrition bias)
All outcomes
High risk Loss to follow up < 20% (8%) Those who died at < 3
months were excluded from analysis
4 in intervention group and 16 in control group were
excluded based on death < 3 months
Selective reporting (reporting bias) Low risk Noprotocol available; all expected outcomes reported.
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Revankar 1998 (Continued)
Other bias High risk Baseline characteristics not described. No description
of baseline ART status
Schuman 1997
Methods Study design: RCT
Participants Inclusion criteria: age >13 years, HIV (western blot or enzyme immunoassay), CD4 <
300
Exclusion criteria: history of Candida oesophagitis, receiving systemic antifungals,
known intolerance of azoles, current pregnancy or lactating
Number randomized: 323
Descriptive baseline data:
• Age (mean): fluconazole (37); placebo (37)
• Sex [% male]: not reported
• CD4 count [median cells/mm³]: fluconazole (172); placebo (186)
• ART regimen provided: non-triple
• Time to ART: not reported
• CrAg status: not reported
• % on ART: fluconazole (85%); placebo (75%)
• Duration of follow-up [median (months)]: 29
Dropouts during study period: fluconazole (5%); placebo (10%)
Interventions • Fluconazole 200 mg weekly
• Placebo
Outcomes • Fluconazole resistance over 29 months
Notes Location: USA
Setting: multicentre: urban, 14 sites participating in the community programmes for
clinical research
Dates: May 1992 to January 1994
Funding: The trial was supported by the National Institute of Allergies and Infectious
Diseases (NIAD)
Others:Open label fluconazole was permitted for candidiasis prophylaxis was permitted
after two oropharyngeal episodes or one episode of vaginal or oesophageal
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk “patients were randomly assigned to received weekly fluconazole
or placebo using a permuted block schemewith randomlymixed
block sizes of two and four”
Allocation concealment (selection bias) Unclear risk Allocation concealment not discussed
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Schuman 1997 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as “double blind”, and no subjective outcomes as-
sessed
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Blinding of laboratory assessors analysing Candida isolates not
described, assessment of Candida resistance may be subjective
Incomplete outcome data (attrition bias)
All outcomes
Low risk “95% of surviving patients receiving fluconazole and 90% of
patients receiving placebo attended follow-up 6 months after
finishing the trial
Selective reporting (reporting bias) Low risk All outcomes mentioned in the methods section were reported.
No protocol available
Other bias Low risk ”Staff members from NIAID (funding body) were part of the
protocol team but had no role in decision to publish the study
Smith 2001
Methods Study design: RCT
Participants Inclusion criteria: documented HIV-1 infection and average of two CD4 counts of <
300 cells/mL within the past 4 months
Exclusion criteria: womenwhowere pregnant or not using reliable contraception, severe
hepatic impairment, known hypersensitivity to azole compounds, a history of previous
systemic fungal infection (including oesophageal candidosis) or any fungal infection
unresponsive to azole therapy and use of systemic antifungal agents, rifabutin, rifampicin,
phenytoin, terfenadine, astemizole, anticholinergic agents, or H2 antagonists
Number randomized: 374 participants
Descriptive baseline data:
• Age [mean (SD)]: itraconazole 37.8 (8.55); placebo 37.6 (8.38)
• Sex [% male]: itraconazole 95.2%; placebo 92%
• CD4 count [mean (SD) cells/mm³]: itraconazole 200 (310); placebo 200 (190)
• ART regimen provided: non-triple
• Time to ART: not reported
• CrAg status: not reported
• % on ART: itraconazole (79%); placebo (73%)
• Duration of follow-up (weeks): 104
Dropouts during study period: itraconazole (9%); placebo (6%)
Interventions • Itraconazole 200 mg daily
• Placebo
Outcomes • All-cause mortality at 2 years
• Cryptococcal disease incidence over 2 years
• Treatment discontinuation over 2 years
• Adverse events over 2 years
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Smith 2001 (Continued)
Notes Location: multicentre; Australia, Canada, South Africa, UK
Setting: clinic
Dates: January 1994 to October 1997
Funding: The trial was funded by the Janssen Research Foundation.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomization was performed by a computer generated code
Allocation concealment (selection bias) Unclear risk No description of methods of allocation concealment docu-
mented
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Described as double blind. Patients received matching placebo
or study medication
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Study was described as double-blind. The authors did not ex-
plicitly state that the outcome assessors were blinded. However,
the outcomes we assessed in this review were mostly objective
Incomplete outcome data (attrition bias)
All outcomes
Low risk Less than 10% loss to follow-up over 2 years.
Selective reporting (reporting bias) Low risk All expected outcomes reported, no protocol available
Other bias Unclear risk Role of Janssen research foundation in design of study and any
analysis unclear
Abbreviations: CD4: cluster of differentiation 4; OPC: oropharyngeal candidiasis; EC: oesophageal candidiasis.
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Anonymous 1995 This was an editorial report of another study.
Anonymous 2001 This was a systematic review.
Apisarnthanarak 2008a This was a retrospective study.
Chaiwarith 2011 This was a retrospective cohort study.
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(Continued)
Chaiwarith 2013 The patients included in this study were on secondary prophylaxis for cryptococcal infection
Geletko 1996 This was a cross-over study.
Havlir 1998 The comparator in this study was not placebo or no intervention
Jüst-Nubling 1991 This study did not report on any of the outcomes we were interested in for this review
Manfredi 1997 This was a retrospective study.
Manosuthi 2005 This was a retrospective cohort study.
Manosuthi 2006 This was a retrospective cohort study.
Mfinanga 2015 The intervention evaluated in this study was community support combined with serum cryptococcal
antigen screening
Micol 2010 This was a cost-effectiveness study.
Mylonakis 1998 This was an editorial report of another study.
Penzak 1998 This was an editorial report.
Powderly 1995 The comparator was not placebo or no intervention.
Singh 1996 The participants in this study were not randomized.
Stevens 1991 This study did not report on any of the outcomes we were interested in
Svoboda 1995 This was a narrative review.
Thurey 2008 This was a systematic review.
Wakeham 2010 This study did not report on any of the outcomes we were interested in for this review
White 1993 This was a narrative review.
Characteristics of studies awaiting assessment [ordered by study ID]
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Anonymous 1998
Methods Not known
Participants HIV-positive women
Interventions Not known
Outcomes Not known
Notes Abstract and full-text unavailable for screening
Smith 1999
Methods RCT
Participants Number of participants (N): 70 participants
Interventions 1. Itraconazole 200 mg daily
2. Placebo
Outcomes 1. Treatment discontinuation
2. Adverse events
Notes Full text unavailable for screening
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D A T A A N D A N A L Y S E S
Comparison 1. Antifungal versus no antifungal (placebo or standard care)
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 All-cause mortality 6 3220 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.80, 1.43]
2 All-cause mortality by CD4
count
6 3190 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.75, 1.42]
2.1 CD4 < 100 1 90 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.05, 1.02]
2.2 CD4 < 150 2 1124 Risk Ratio (M-H, Random, 95% CI) 1.38 [0.99, 1.93]
2.3 CD4 < 200 2 1648 Risk Ratio (M-H, Random, 95% CI) 1.04 [0.81, 1.34]
2.4 CD4 < 300 1 328 Risk Ratio (M-H, Random, 95% CI) 0.54 [0.24, 1.20]
3 All-cause mortality by baseline
CrAG status
6 3220 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.80, 1.43]
3.1 CrAG-negative at baseline 2 1609 Risk Ratio (M-H, Random, 95% CI) 0.59 [0.14, 2.43]
3.2 No CrAG screening 4 1611 Risk Ratio (M-H, Random, 95% CI) 1.22 [0.91, 1.63]
4 All-cause mortality by time-to-
ART initiation
6 3220 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.80, 1.43]
4.1 Triple ART; median 11
weeks to initiation
1 1519 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.79, 1.35]
4.2 No triple ART; > 11 weeks
to initiation
5 1701 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.67, 1.59]
5 All-cause mortality by ART
received
6 3220 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.80, 1.43]
5.1 Single or dual ART 5 1701 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.67, 1.59]
5.2 Triple ART 1 1519 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.79, 1.35]
6 All-cause mortality by type of
antifungal drug
6 Risk Ratio (M-H, Random, 95% CI) Subtotals only
6.1 Flucaonazole 3 2438 Risk Ratio (M-H, Random, 95% CI) 0.99 [0.62, 1.59]
6.2 Itraconazole 3 782 Risk Ratio (M-H, Random, 95% CI) 1.12 [0.70, 1.80]
7 Cryptococcal disease occurrence 7 5000 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.17, 0.49]
8 Cryptococcal disease occurrence
by CD4 count
7 5000 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.17, 0.49]
8.1 CD4 < 100 2 1870 Risk Ratio (M-H, Random, 95% CI) 0.40 [0.21, 0.78]
8.2 CD4 < 150 2 1124 Risk Ratio (M-H, Random, 95% CI) 0.25 [0.08, 0.76]
8.3 CD4 < 200 2 1648 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.01, 0.31]
8.4 CD4 < 300 1 358 Risk Ratio (M-H, Random, 95% CI) 0.2 [0.01, 4.14]
9 Cryptococcal disease occurrence
by ART received
7 5000 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.17, 0.49]
9.1 No triple ART 5 1701 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.13, 0.60]
9.2 Triple ART 2 3299 Risk Ratio (M-H, Random, 95% CI) 0.18 [0.03, 1.30]
10 Cryptococcal disease
occurrence by type of
antifungal drug
7 5000 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.17, 0.49]
10.1 Fluconazole 4 4218 Risk Ratio (M-H, Random, 95% CI) 0.32 [0.16, 0.62]
10.2 Itraconazole 3 782 Risk Ratio (M-H, Random, 95% CI) 0.12 [0.03, 0.51]
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11 Cryptococcal disease
occurrence by time-to-ART
initiation
7 5000 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.17, 0.49]
11.1 ART commenced;
median 5 days after screening
1 1780 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.18, 0.84]
11.2 ART commenced;
median 11 weeks after
diagnosis
1 1519 Risk Ratio (M-H, Random, 95% CI) 0.06 [0.01, 0.41]
11.3 ART commenced;
median > 11 weeks after
diagnosis
5 1701 Risk Ratio (M-H, Random, 95% CI) 0.28 [0.13, 0.60]
12 Cryptococcal disease
occurrence by baseline CrAg
status
7 Risk Ratio (M-H, Random, 95% CI) Subtotals only
12.1 CrAG-negative at
baseline
3 3257 Risk Ratio (M-H, Random, 95% CI) 0.23 [0.06, 0.90]
12.2 CrAG-positive at
baseline
1 133 Risk Ratio (M-H, Random, 95% CI) 0.39 [0.15, 1.01]
12.3 No CrAG screening 4 1611 Risk Ratio (M-H, Random, 95% CI) 0.21 [0.08, 0.56]
13 Cryptococcal-specific mortality 5 3813 Risk Ratio (M-H, Random, 95% CI) 0.29 [0.11, 0.72]
14 Clinical resistance of Candida
to antifungal
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
14.1 Fluconazole 3 1198 Risk Ratio (M-H, Random, 95% CI) 0.93 [0.56, 1.56]
14.2 Itraconazole 1 129 Risk Ratio (M-H, Random, 95% CI) 3.14 [0.13, 75.69]
15 Microbiological resistance of
Candida to fluconazole
4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
15.1 Surveillance sampling,
fluconazole used, all Candida
species
3 539 Risk Ratio (M-H, Random, 95% CI) 1.25 [1.00, 1.55]
15.2 Sampling from clinical
disease, itraconazole used, C.
albicans only
1 95 Risk Ratio (M-H, Random, 95% CI) 6.19 [1.41, 27.10]
16 Treatment discontinuation 4 2317 Risk Ratio (M-H, Random, 95% CI) 1.01 [0.91, 1.13]
17 Any serious adverse event 4 888 Risk Ratio (M-H, Random, 95% CI) 1.08 [0.83, 1.41]
18 Any adverse events 4 2317 Risk Ratio (M-H, Random, 95% CI) 1.07 [0.88, 1.30]
19 Common adverse events 4 Risk Ratio (M-H, Random, 95% CI) Subtotals only
19.1 Diarrhoea 2 424 Risk Ratio (M-H, Random, 95% CI) 1.31 [0.32, 5.29]
19.2 Abdominal pain 2 1814 Risk Ratio (M-H, Random, 95% CI) 0.91 [0.56, 1.46]
19.3 Nausea 2 1814 Risk Ratio (M-H, Random, 95% CI) 0.97 [0.64, 1.47]
19.4 Rash 4 2317 Risk Ratio (M-H, Random, 95% CI) 1.03 [0.56, 1.91]
A D D I T I O N A L T A B L E S
Table 1. Key characteristics of included studies
Study ID Country Number
random-
ized
Age
(years)
CD4
threshold
(cells/µL)
Triple
ART regi-
men
Interven-
tion
Time to
ART
Excluded
CrAg +ve
CrAG sta-
tus at
baseline
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Table 1. Key characteristics of included studies (Continued)
Chariyalert-
sak
2002
Thailand 129 Mean 33
(range 22
to 58)
< 200 No Itracona-
zole 200
mg daily +
CTX
NR No NR
Chetchoti-
sakd
2004
Thailand 90 Range: 20
to 53
< 100 No Flucona-
zole 400
mg weekly
NR Yes CrAG-ve:
90/90
Goldman
2005
USA 829 Median 38
(range: 19
to 71)
< 150 No Flucona-
zole 200
mg
three times
per week
NR No NR
Hakim
2017
Uganda,
Zim-
babwe,
Malawi,
Kenya
1805 Median 36
(IQR 29 to
42)
< 100 Yes Enhanced
prophy-
laxis:
flucona-
zole 100
mg daily +
CTX +
INH daily
+ immedi-
ate alben-
dazole + 5
days
of azithro-
mycin
5 days (2 to
8)
No CrAG+ve:
133/1781
McKinsey
1999
USA 295 Median 36
to 37
< 150 No Itracona-
zole 200
mg daily
NR No NR
Parkes-
Ratanshi
2011
Uganda 1519 Mean 36 < 200 Yes Flucona-
zole 200
mg 3 times
per week
11
weeks (me-
dian; IQR
7 to
17 weeks)
; flucona-
zole 82
days;
placebo 87
days
Yes CrAG-ve:
1519/
1519
Revankar
1998
USA 62 NR < 350 Unknown Flucona-
zole 200
mg daily
NR No NR
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Table 1. Key characteristics of included studies (Continued)
Schuman
1997
USA 323 Mean 37 < 300 No Flucona-
zole 200
mg weekly
NR No NR
Smith
2001
Australia,
Canada,
South
Africa, UK
374 Mean 38
(SD 8)
< 300 No Itracona-
zole 200
mg daily
NR No NR
Abbreviations:NR: not reported; ART: antiretroviral therapy;CTX: co-trimoxazole;CD4: cluster of differentiation4; IQR: interquartile
range; +ve: positive; -ve: negative.
Table 2. Clinically defined resistance to fluconazole and itraconazole
Description of studies 2 X 2 table
Study ID Aims of study Definition
of clinical resis-
tance
Prophylaxis
given
Intervention re-
ceived
Number of par-
ticipants with
clinical disease
resistant to flu-
conazole
Number of par-
ticipants
randomized
Clinically defined resistance (episodes of clinical resistance per number of patients randomised): fluconazole
Goldman 2005 To compare flu-
conazole to stan-
dard care for the
preven-
tion of Candida
infections.
Clinical end-
point defined as
persistent or re-
fractory candidi-
asis*
Fluconazole 200
mg three times
weekly
Continuous flu-
conazole
18 413
Standard care 18 416
Revankar 1998 To compare flu-
conazole to stan-
dard care for the
preven-
tion of Candida
infections.
Clinical re-
sistance was de-
fined as the pres-
ence of resistant
isolates (MIC >
16 µg/mL) that
affected response
to therapy
Fluconazole 200
mg daily
Continuous flu-
conazole
2 16
Standard care 5 28
Schuman 1997 To compare flu-
conazole to
placebo for pre-
vention of mu-
cosal candidiasis
in HIV-positive
women
Clini-
cal resistance not
defined
Fluconazole 200
mg once weekly
Fluconazole 6 162
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Table 2. Clinically defined resistance to fluconazole and itraconazole (Continued)
Placebo + Stan-
dard care
7 161
Clinically defined resistance (episodes of clinical resistance per number of patients randomised): itraconazole
Chariyalertsak
2002
To compare Itra-
cona-
zole prophylaxis
to placebo for
the prevention of
deep fungal in-
fections
Clini-
cal resistance de-
fined as candidi-
asis that did not
respond to treat-
ment*
Itraconazole 200
mg daily
Itraconazole 1 63
Placebo + Stan-
dard care
0 66
*Full details of definition of clinical disease available in Characteristics of included studies
Table 3. Microbiologically defined resistance of Candida to fluconazole
Description of studies 2 X 2 table
Study ID Study aims Type of isolate Organism
reported
Intervention re-
ceived
Number of par-
ticipants with at
least 1 isolate
resistant to flu-
conazole (MIC,
> 16 µg/mL)
Number of par-
ticipants with at
least one sample
where Candida
was isolated
Microbiologically defined resistance of Candida to fluconazole (number of patients with at least one resistant isolate): flu-
conazole received
Schuman 1997 To compare flu-
conazole to
placebo for pre-
vention of mu-
cosal candidiasis
in HIV-positive
women
Vaginal mucosal
surveillance
cultures taken 3
monthly
All
Candida species
combined
Fluconazole 29 88
Placebo + Stan-
dard care
21 79
Goldman 2005 To compare flu-
conazole to stan-
dard care for the
preven-
tion of Candida
infections
Surveillance
swab obtained at
end of the study
All
Candida species
combined
Continuous flu-
conazole
50 110
Standard care 79 218
Revankar 1998 To compare flu-
conazole to stan-
dard care for the
preven-
Isolates obtained
from clinical dis-
ease and 3
monthly surveil-
All
Candida species
combined
Continuous flu-
conazole
9 16
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Table 3. Microbiologically defined resistance of Candida to fluconazole (Continued)
tion of Candida
infections
lance swabs
Standard care 13 28
Microbiologically-defined resistance of Candida to fluconazole (number of patients with at least one resistant isolate): itra-
conazole received, cross-resistance to fluconazole reported
McKinsey 1999 To compare Itra-
conazole
to placebo for
the prevention of
deep fungal in-
fections (includ-
ing cryptococcal
disease)
Vaginal
and oesophageal
mucosal isolates
from clinical dis-
ease occurrences
C. albicans only
(Other species
not reported)
Itraconazole 9/40*
patients had iso-
lates reported as
‘not susceptible’
40
Placebo + Stan-
dard care
2/55*
patients had iso-
lates reported as
‘not susceptible’
55
*Itraconazole received, cross resistance to fluconazole reported.
Table 4. Reasons for discontinuation of antifungal prophylaxis
Treatment discontinuation (cause) Antifungal group Placebo group
Chariyalertsak 2002 (N = 129)
Access disallowed medicationsa 3 (2.3%) 3 (2.3%)
Adverse events 2 (1.6%) 1 (0.7%)
Hepatotoxicity 1 (0.7%) 1 (0.7%)
Patient choice 14 (11%) 9 (6.9%)
McKinsey 1999 (N = 295)
Adverse events 13 (4.4%) 5 (1.7%)
Patient choice 27 (9.1%) 36 (12%)
Parkes-Ratanshi 2011 (N = 1519)
Loss to follow-up 31 (2%) 19 (1.3%)
Patient choice 11 (0.7%) 4 (0.3%)
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Table 4. Reasons for discontinuation of antifungal prophylaxis (Continued)
Safety concerns 59 (3.8%) 59 (3.8%)
Smith 2001 (N = 374)
Access disallowed medicationsa 15 (4%) 3 (0.8%)
Adverse event 31 (8.3%) 29 (7.8%)
Hepatotoxicity 2 (0.5%) 3 (0.8%)
Patient choice 33 (8.8%) 46 (12%)
Pregnancy 0 (0%) 1 (0.3%)
Other 37(9.9%) 42 (11%)
aWe defined this as the number of participants who had to discontinue the study medication because of the need to take other
medication that interfered with itraconazole serum levels.
WH A T ’ S N E W
Last assessed as up-to-date: 31 August 2017.
Date Event Description
28 August 2018 New search has been performed This is an update of a review last published in 2005
(Chang 2005). The review author team updated the pro-
tocol extensively, and differences are highlighted in the ‘
Differences between protocol and review’ section.
28 August 2018 New citation required and conclusions have changed Nine trials (5426 participants) met the inclusion criteria
of this review update.One study included in the Chang
2005 review did not meet our inclusion criteria. We also
included two studies published after the Chang 2005 re-
view (Hakim 2017; Parkes-Ratanshi 2011).
We considered outcomes related to resistance in trials
looking at prevention of Candida infection, which were
not included in the Chang 2005 review.
The findings of this review update are consistent with
those of previous published reviews, which both showed
that antifungal prophylaxis may havemade little or no dif-
ference to all-cause mortality, but reduced the occurrence
of cryptococcal disease (Chang 2005; Ssekitoleko 2013).
However, the findings from this review are more relevant
to current HIV populations
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D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
This is an update of a previous Cochrane review (Chang 2005). The new review author team extensively revised the protocol, which
is available on the CIDG website at cidg.cochrane.org/our-reviews under the subheading ‘Related content’.
Several outcomes that were not originally included in the protocol were added during the review process. This included mortality due
to cryptococcal disease and microbiological resistance in Candida species. We included these outcomes to clarify the benefits and harms
of the intervention.
Adherence was reported as described in the trial.
Several outcomes measures changed from rate to proportion. There was no intention of analysing these outcomes as rates and the teams
intention was always to look at proportions, however incorrect wording was used in the published protocol and this was corrected in
the final review.
We counted cases of cryptococcal disease in the studies if the investigators referred to them as confirmed cases. We did not count cases
that the authors referred to as suspected. We also didn’t rely on the study authors specifically describing the method of diagnosis.
We included studies that didn’t specify the method of cryptococcal diagnosis.
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We included studies that gave co-trimoxazole prophylaxis in both groups, as we decided that in order for the review to be relevant in
today’s setting, we would need to include studies where standardHIV co-interventions, such as co-trimoxazole and isoniazid prophylaxis
were provided.
We included studies that provided other co-interventions with antifungal prophylaxis. We felt this was necessary in order to include
the most recent and applicable evidence. We minimized the confounding effect of the co-interventions as described previously.
Candida resistance to fluconazole was assessed by microbiological assessment and not restricted to clinical diseases. We used an MIC >
16 µg/mL to define resistance to fluconazole, according to the majority of the study definitions.
We amended the comparator to placebo or no antifungal intervention in response to peer review comments.
We amended our subgroup analyses in response to peer review comments to include the following subgroups for all-cause mortality
and cryptococcal disease occurrence.
• CD4+ threshold for initiation of prophylaxis
• CrAg status at baseline
• Timing of ART initiation
• Type of ART
• Type of antifungal drug
I N D E X T E R M S
Medical Subject Headings (MeSH)
AIDS-RelatedOpportunistic Infections [∗prevention & control]; Antifungal Agents [∗therapeutic use]; Cryptococcosis [∗prevention &
control]; Fluconazole [therapeutic use]; Itraconazole [therapeutic use]; Meningitis, Cryptococcal [prevention & control]; Randomized
Controlled Trials as Topic
MeSH check words
Adult; Humans
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